https://trial.medpath.com/news/metsera-to-showcase-next-generation-obesity-therapies-at-ada-2025-with-clinical-data-from-ultra-long-acting-glp-1-agonist 2025-06-05T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metsera-to-showcase-next-generation-obesity-therapies-at-ada-2025-with-clinical-data-from-ultra-long-acting-glp-1-agonist 2025-06-05T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-analysis-of-methotrexate-safety-profile-reveals-gender-and-age-specific-adverse-event-patterns 2025-06-05T07:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-analysis-of-methotrexate-safety-profile-reveals-gender-and-age-specific-adverse-event-patterns 2025-06-05T07:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/unf-researchers-advance-cancer-fighting-compound-to-animal-trials-after-breakthrough-discovery 2025-06-05T06:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unf-researchers-advance-cancer-fighting-compound-to-animal-trials-after-breakthrough-discovery 2025-06-05T06:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/acerand-therapeutics-initiates-first-in-human-trial-of-novel-cyp11a1-inhibitor-ace-232-for-advanced-prostate-cancer 2025-06-05T05:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acerand-therapeutics-initiates-first-in-human-trial-of-novel-cyp11a1-inhibitor-ace-232-for-advanced-prostate-cancer 2025-06-05T05:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/openwater-s-portable-stroke-detection-device-shows-promise-in-field-diagnostics-and-rehabilitation-research 2025-06-05T05:03:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/openwater-s-portable-stroke-detection-device-shows-promise-in-field-diagnostics-and-rehabilitation-research 2025-06-05T05:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-denies-approval-for-elamipretide-forcing-stealth-biotherapeutics-to-halt-production-of-rare-disease-treatment 2025-06-05T05:03:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-denies-approval-for-elamipretide-forcing-stealth-biotherapeutics-to-halt-production-of-rare-disease-treatment 2025-06-05T05:03:28+00:00 hourly 0.9 https://trial.medpath.com/news/tivozanib-monotherapy-shows-promise-as-second-line-treatment-for-metastatic-rcc-following-contemporary-immunotherapy 2025-06-05T05:02:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tivozanib-monotherapy-shows-promise-as-second-line-treatment-for-metastatic-rcc-following-contemporary-immunotherapy 2025-06-05T05:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/terthera-launches-world-s-first-gmp-compliant-terbium-161-for-enhanced-cancer-radiotherapy 2025-06-05T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terthera-launches-world-s-first-gmp-compliant-terbium-161-for-enhanced-cancer-radiotherapy 2025-06-05T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/mallia-completes-eur5-5m-seed-funding-to-advance-scd83-based-hair-loss-treatments 2025-06-05T03:57:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mallia-completes-eur5-5m-seed-funding-to-advance-scd83-based-hair-loss-treatments 2025-06-05T03:57:08+00:00 hourly 0.9 https://trial.medpath.com/news/rakuten-medical-secures-amed-funding-for-novel-pd-l1-photoimmunotherapy-rm-0256 2025-06-05T03:03:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rakuten-medical-secures-amed-funding-for-novel-pd-l1-photoimmunotherapy-rm-0256 2025-06-05T03:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/nucleus-genomics-launches-first-genetic-optimization-software-for-ivf-embryo-selection 2025-06-05T03:00:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nucleus-genomics-launches-first-genetic-optimization-software-for-ivf-embryo-selection 2025-06-05T03:00:07+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-model-outperforms-individual-biomarkers-in-predicting-advanced-renal-cell-carcinoma-treatment-response 2025-06-05T02:58:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-model-outperforms-individual-biomarkers-in-predicting-advanced-renal-cell-carcinoma-treatment-response 2025-06-05T02:58:32+00:00 hourly 0.9 https://trial.medpath.com/news/ret-inhibitor-rechallenge-shows-promise-in-pre-treated-nsclc-patients-after-toxicity-related-discontinuation 2025-06-05T01:57:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ret-inhibitor-rechallenge-shows-promise-in-pre-treated-nsclc-patients-after-toxicity-related-discontinuation 2025-06-05T01:57:16+00:00 hourly 0.9 https://trial.medpath.com/news/mycovia-pharmaceuticals-initiates-phase-2-trial-of-oteseconazole-for-cryptococcal-meningitis 2025-06-05T01:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mycovia-pharmaceuticals-initiates-phase-2-trial-of-oteseconazole-for-cryptococcal-meningitis 2025-06-05T01:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/toyobo-and-dmc-biotechnologies-partner-to-develop-sustainable-chemical-intermediates-through-precision-fermentation 2025-06-05T01:05:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/toyobo-and-dmc-biotechnologies-partner-to-develop-sustainable-chemical-intermediates-through-precision-fermentation 2025-06-05T01:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/zigakibart-shows-sustained-60-proteinuria-reduction-in-100-week-iga-nephropathy-study 2025-06-05T01:01:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zigakibart-shows-sustained-60-proteinuria-reduction-in-100-week-iga-nephropathy-study 2025-06-05T01:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-develop-milli-spinner-technology-that-doubles-blood-clot-removal-effectiveness 2025-06-05T01:01:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-researchers-develop-milli-spinner-technology-that-doubles-blood-clot-removal-effectiveness 2025-06-05T01:01:20+00:00 hourly 0.9 https://trial.medpath.com/news/ai-breakthrough-accelerates-protein-engineering-for-next-generation-therapeutics 2025-06-05T00:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-breakthrough-accelerates-protein-engineering-for-next-generation-therapeutics 2025-06-05T00:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/bnt113-cancer-vaccine-shows-promise-in-phase-ii-iii-trial-for-hpv16-head-and-neck-cancer 2025-06-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bnt113-cancer-vaccine-shows-promise-in-phase-ii-iii-trial-for-hpv16-head-and-neck-cancer 2025-06-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/knight-therapeutics-acquires-sumitomo-s-canadian-portfolio-including-myfembree-and-orgovyx-for-c-25-4-million 2025-06-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/knight-therapeutics-acquires-sumitomo-s-canadian-portfolio-including-myfembree-and-orgovyx-for-c-25-4-million 2025-06-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/highridge-medical-divests-bone-healing-division-to-focus-on-core-spine-technologies 2025-06-04T23:58:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/highridge-medical-divests-bone-healing-division-to-focus-on-core-spine-technologies 2025-06-04T23:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/trisalus-launches-enhanced-trinav-flx-infusion-system-for-improved-tumor-drug-delivery 2025-06-04T23:55:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trisalus-launches-enhanced-trinav-flx-infusion-system-for-improved-tumor-drug-delivery 2025-06-04T23:55:45+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-medical-care-advances-u-s-rollout-of-high-volume-hemodiafiltration-following-fda-clearance 2025-06-04T22:52:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresenius-medical-care-advances-u-s-rollout-of-high-volume-hemodiafiltration-following-fda-clearance 2025-06-04T22:52:40+00:00 hourly 0.9 https://trial.medpath.com/news/elucidata-and-sapien-biosciences-form-strategic-partnership-to-transform-india-s-largest-biobank-into-ai-ready-data-platform 2025-06-04T22:51:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elucidata-and-sapien-biosciences-form-strategic-partnership-to-transform-india-s-largest-biobank-into-ai-ready-data-platform 2025-06-04T22:51:43+00:00 hourly 0.9 https://trial.medpath.com/news/aitia-partners-with-gustave-roussy-to-develop-ai-powered-digital-twins-for-cancer-research 2025-06-04T21:54:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aitia-partners-with-gustave-roussy-to-develop-ai-powered-digital-twins-for-cancer-research 2025-06-04T21:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/new-research-reveals-complex-effects-of-ozempic-on-muscle-mass-and-strength 2025-06-04T21:43:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-research-reveals-complex-effects-of-ozempic-on-muscle-mass-and-strength 2025-06-04T21:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-s-new-ceo-charts-course-for-adc-expansion-beyond-enhertu-success 2025-06-04T20:56:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-s-new-ceo-charts-course-for-adc-expansion-beyond-enhertu-success 2025-06-04T20:56:35+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-moderna-victory-in-covid-19-vaccine-patent-dispute-with-alnylam 2025-06-04T20:56:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-upholds-moderna-victory-in-covid-19-vaccine-patent-dispute-with-alnylam 2025-06-04T20:56:15+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-funding-plummets-57-to-2-7-billion-as-trump-administration-policies-shake-investor-confidence 2025-06-04T20:54:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-funding-plummets-57-to-2-7-billion-as-trump-administration-policies-shake-investor-confidence 2025-06-04T20:54:53+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-gsk-pursue-aggressive-m-a-strategies-while-mrna-technology-faces-economic-headwinds 2025-06-04T20:53:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-and-gsk-pursue-aggressive-m-a-strategies-while-mrna-technology-faces-economic-headwinds 2025-06-04T20:53:27+00:00 hourly 0.9 https://trial.medpath.com/news/thio-plus-cemiplimab-demonstrates-promising-activity-in-ici-resistant-advanced-nsclc 2025-06-04T20:52:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thio-plus-cemiplimab-demonstrates-promising-activity-in-ici-resistant-advanced-nsclc 2025-06-04T20:52:55+00:00 hourly 0.9 https://trial.medpath.com/news/kfshrc-achieves-breakthrough-in-gene-therapy-for-hemophilia-a-with-one-time-treatment-success 2025-06-04T20:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kfshrc-achieves-breakthrough-in-gene-therapy-for-hemophilia-a-with-one-time-treatment-success 2025-06-04T20:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/china-courts-signal-shift-in-polymorph-patent-standards-as-beijing-ip-court-lowers-inventiveness-bar 2025-06-04T20:02:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-courts-signal-shift-in-polymorph-patent-standards-as-beijing-ip-court-lowers-inventiveness-bar 2025-06-04T20:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-awards-sarepta-first-platform-technology-designation-for-gene-therapy-vector 2025-06-04T18:59:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-awards-sarepta-first-platform-technology-designation-for-gene-therapy-vector 2025-06-04T18:59:55+00:00 hourly 0.9 https://trial.medpath.com/news/carbogen-amcis-secures-chf-25-million-co-investment-to-expand-adc-drug-linker-manufacturing-in-switzerland 2025-06-04T17:58:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carbogen-amcis-secures-chf-25-million-co-investment-to-expand-adc-drug-linker-manufacturing-in-switzerland 2025-06-04T17:58:45+00:00 hourly 0.9 https://trial.medpath.com/news/cepheid-receives-health-canada-approval-for-next-generation-hiv-viral-load-test 2025-06-04T17:57:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepheid-receives-health-canada-approval-for-next-generation-hiv-viral-load-test 2025-06-04T17:57:07+00:00 hourly 0.9 https://trial.medpath.com/news/vividion-secures-exclusive-rights-to-first-in-class-wrn-inhibitor-vvd-214-for-msi-high-cancers 2025-06-04T16:56:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vividion-secures-exclusive-rights-to-first-in-class-wrn-inhibitor-vvd-214-for-msi-high-cancers 2025-06-04T16:56:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-drug-free-wearable-device-for-pediatric-nasal-congestion-treatment 2025-06-04T16:55:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-drug-free-wearable-device-for-pediatric-nasal-congestion-treatment 2025-06-04T16:55:58+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-oncology-trials-rarely-demonstrate-meaningful-survival-and-quality-of-life-improvements 2025-06-04T16:54:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-oncology-trials-rarely-demonstrate-meaningful-survival-and-quality-of-life-improvements 2025-06-04T16:54:45+00:00 hourly 0.9 https://trial.medpath.com/news/iambic-therapeutics-advances-ai-designed-her2-inhibitor-iam1363-to-dose-optimization-phase 2025-06-04T16:53:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iambic-therapeutics-advances-ai-designed-her2-inhibitor-iam1363-to-dose-optimization-phase 2025-06-04T16:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/eib-provides-eur30m-to-treefrog-therapeutics-for-parkinson-s-disease-cell-therapy-development 2025-06-04T16:51:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eib-provides-eur30m-to-treefrog-therapeutics-for-parkinson-s-disease-cell-therapy-development 2025-06-04T16:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/biocytogen-and-nanjing-chia-tai-tianqing-receive-ind-approval-for-second-generation-anti-igf-1r-antibody-ntb003-in-thyroid-eye-disease 2025-06-04T16:51:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocytogen-and-nanjing-chia-tai-tianqing-receive-ind-approval-for-second-generation-anti-igf-1r-antibody-ntb003-in-thyroid-eye-disease 2025-06-04T16:51:21+00:00 hourly 0.9 https://trial.medpath.com/news/oncovita-receives-fda-orphan-drug-designation-for-oncolytic-measles-virus-therapy-in-pleural-mesothelioma 2025-06-04T16:49:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncovita-receives-fda-orphan-drug-designation-for-oncolytic-measles-virus-therapy-in-pleural-mesothelioma 2025-06-04T16:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/carbogen-amcis-shanghai-facility-receives-first-drug-manufacturing-license-from-china-s-nmpa 2025-06-04T16:49:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carbogen-amcis-shanghai-facility-receives-first-drug-manufacturing-license-from-china-s-nmpa 2025-06-04T16:49:30+00:00 hourly 0.9 https://trial.medpath.com/news/repertoire-immune-medicines-appoints-oncology-veteran-as-cmo-advances-tcr-bispecific-toward-phase-1-2-trial 2025-06-04T16:49:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repertoire-immune-medicines-appoints-oncology-veteran-as-cmo-advances-tcr-bispecific-toward-phase-1-2-trial 2025-06-04T16:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/lipella-pharmaceuticals-renews-manufacturing-partnership-with-cook-myosite-to-advance-oral-lichen-planus-treatment 2025-06-04T16:49:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipella-pharmaceuticals-renews-manufacturing-partnership-with-cook-myosite-to-advance-oral-lichen-planus-treatment 2025-06-04T16:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/usp-opens-advanced-technologies-laboratory-to-strengthen-pharmaceutical-supply-chains-and-manufacturing 2025-06-04T16:49:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usp-opens-advanced-technologies-laboratory-to-strengthen-pharmaceutical-supply-chains-and-manufacturing 2025-06-04T16:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-launches-firstgene-multiple-prenatal-screen-with-four-in-one-testing-capability 2025-06-04T16:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-launches-firstgene-multiple-prenatal-screen-with-four-in-one-testing-capability 2025-06-04T16:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/vadadustat-phase-3-data-reveals-geographic-differences-in-ckd-anemia-treatment-outcomes 2025-06-04T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vadadustat-phase-3-data-reveals-geographic-differences-in-ckd-anemia-treatment-outcomes 2025-06-04T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/ema-issues-strategic-recommendations-to-address-critical-radiopharmaceutical-supply-chain-vulnerabilities-in-europe 2025-06-04T16:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-issues-strategic-recommendations-to-address-critical-radiopharmaceutical-supply-chain-vulnerabilities-in-europe 2025-06-04T16:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-issues-first-uk-guidance-for-phage-therapy-development-to-combat-antibiotic-resistant-infections 2025-06-04T16:48:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-issues-first-uk-guidance-for-phage-therapy-development-to-combat-antibiotic-resistant-infections 2025-06-04T16:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-kabi-launches-first-generic-iodixanol-contrast-agent-in-canada-addressing-critical-supply-shortages 2025-06-04T16:47:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresenius-kabi-launches-first-generic-iodixanol-contrast-agent-in-canada-addressing-critical-supply-shortages 2025-06-04T16:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/annamycin-shows-59-clinical-benefit-rate-in-soft-tissue-sarcoma-lung-metastases-phase-2-trial 2025-06-04T16:46:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annamycin-shows-59-clinical-benefit-rate-in-soft-tissue-sarcoma-lung-metastases-phase-2-trial 2025-06-04T16:46:44+00:00 hourly 0.9 https://trial.medpath.com/news/halia-therapeutics-completes-enrollment-in-phase-2a-trial-of-novel-nlrp3-inflammasome-inhibitor-for-myelodysplastic-syndrome 2025-06-04T16:46:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halia-therapeutics-completes-enrollment-in-phase-2a-trial-of-novel-nlrp3-inflammasome-inhibitor-for-myelodysplastic-syndrome 2025-06-04T16:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/biodexa-initiates-phase-2-trial-of-tolimidone-for-type-1-diabetes-treatment 2025-06-04T16:45:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biodexa-initiates-phase-2-trial-of-tolimidone-for-type-1-diabetes-treatment 2025-06-04T16:45:49+00:00 hourly 0.9 https://trial.medpath.com/news/commit-biologics-forms-scientific-advisory-board-to-advance-complement-based-cancer-and-autoimmune-therapies 2025-06-04T14:58:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/commit-biologics-forms-scientific-advisory-board-to-advance-complement-based-cancer-and-autoimmune-therapies 2025-06-04T14:58:32+00:00 hourly 0.9 https://trial.medpath.com/news/tata-memorial-centre-partners-with-ge-healthcare-to-establish-advanced-cancer-research-innovation-centre 2025-06-04T12:59:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tata-memorial-centre-partners-with-ge-healthcare-to-establish-advanced-cancer-research-innovation-centre 2025-06-04T12:59:55+00:00 hourly 0.9 https://trial.medpath.com/news/continuity-biosciences-acquires-focal-medical-to-advance-iontophoresis-based-pancreatic-cancer-therapy 2025-06-04T12:58:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/continuity-biosciences-acquires-focal-medical-to-advance-iontophoresis-based-pancreatic-cancer-therapy 2025-06-04T12:58:20+00:00 hourly 0.9 https://trial.medpath.com/news/buscar-company-acquires-70-stake-in-armorgenix-to-enter-pharmaceutical-market 2025-06-04T12:58:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/buscar-company-acquires-70-stake-in-armorgenix-to-enter-pharmaceutical-market 2025-06-04T12:58:09+00:00 hourly 0.9 https://trial.medpath.com/news/elpis-biopharmaceuticals-partners-with-singapore-general-hospital-to-advance-next-generation-car-gdt-therapies-for-blood-cancers 2025-06-04T12:57:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elpis-biopharmaceuticals-partners-with-singapore-general-hospital-to-advance-next-generation-car-gdt-therapies-for-blood-cancers 2025-06-04T12:57:49+00:00 hourly 0.9 https://trial.medpath.com/news/m42-astrazeneca-and-sophia-genetics-launch-uae-liquid-biopsy-initiative-to-transform-cancer-diagnosis 2025-06-04T12:57:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/m42-astrazeneca-and-sophia-genetics-launch-uae-liquid-biopsy-initiative-to-transform-cancer-diagnosis 2025-06-04T12:57:29+00:00 hourly 0.9 https://trial.medpath.com/news/leon-nanodrugs-appoints-dr-wolfgang-hofmann-as-ceo-to-drive-nanoparticle-manufacturing-technology-commercialization 2025-06-04T12:57:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leon-nanodrugs-appoints-dr-wolfgang-hofmann-as-ceo-to-drive-nanoparticle-manufacturing-technology-commercialization 2025-06-04T12:57:09+00:00 hourly 0.9 https://trial.medpath.com/news/wildtype-becomes-first-company-to-launch-cultivated-seafood-in-us-market-following-fda-clearance 2025-06-04T12:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wildtype-becomes-first-company-to-launch-cultivated-seafood-in-us-market-following-fda-clearance 2025-06-04T12:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-health-and-axxam-form-strategic-partnership-to-accelerate-ai-driven-drug-target-discovery 2025-06-04T12:56:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-health-and-axxam-form-strategic-partnership-to-accelerate-ai-driven-drug-target-discovery 2025-06-04T12:56:29+00:00 hourly 0.9 https://trial.medpath.com/news/saniona-advances-neurological-pipeline-with-strategic-partnerships-and-strong-financial-position 2025-06-04T12:56:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saniona-advances-neurological-pipeline-with-strategic-partnerships-and-strong-financial-position 2025-06-04T12:56:20+00:00 hourly 0.9 https://trial.medpath.com/news/patent-settlements-accelerate-generic-and-biosimilar-market-entry-generating-423-billion-in-healthcare-savings 2025-06-04T12:55:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patent-settlements-accelerate-generic-and-biosimilar-market-entry-generating-423-billion-in-healthcare-savings 2025-06-04T12:55:56+00:00 hourly 0.9 https://trial.medpath.com/news/purple-biotech-to-present-novel-captn-3-tri-specific-antibody-platform-at-eacr-2025 2025-06-04T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purple-biotech-to-present-novel-captn-3-tri-specific-antibody-platform-at-eacr-2025 2025-06-04T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-trials-launches-remote-telehealth-pre-screening-to-expand-access-for-regional-patients 2025-06-04T10:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-cancer-trials-launches-remote-telehealth-pre-screening-to-expand-access-for-regional-patients 2025-06-04T10:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/traws-pharma-stock-surges-94-following-breakthrough-drug-trial-success 2025-06-04T10:56:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traws-pharma-stock-surges-94-following-breakthrough-drug-trial-success 2025-06-04T10:56:33+00:00 hourly 0.9 https://trial.medpath.com/news/ai-guided-drug-discovery-identifies-promising-cancer-treatment-combinations-using-existing-non-cancer-medications 2025-06-04T09:56:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-guided-drug-discovery-identifies-promising-cancer-treatment-combinations-using-existing-non-cancer-medications 2025-06-04T09:56:23+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-drug-combination-outperforms-keytruda-in-advanced-lung-cancer-trial 2025-06-04T09:01:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-drug-combination-outperforms-keytruda-in-advanced-lung-cancer-trial 2025-06-04T09:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/fujirebio-launches-automated-strem2-assay-to-advance-neuroinflammation-research-in-alzheimer-s-disease 2025-06-04T09:00:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujirebio-launches-automated-strem2-assay-to-advance-neuroinflammation-research-in-alzheimer-s-disease 2025-06-04T09:00:46+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-advances-bi-1910-anti-tnfr2-antibody-with-population-modeling-data-at-page-2025 2025-06-04T09:00:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-advances-bi-1910-anti-tnfr2-antibody-with-population-modeling-data-at-page-2025 2025-06-04T09:00:33+00:00 hourly 0.9 https://trial.medpath.com/news/caltech-s-smart-bandage-technology-demonstrates-early-biomarker-detection-in-first-human-clinical-trial 2025-06-04T09:00:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caltech-s-smart-bandage-technology-demonstrates-early-biomarker-detection-in-first-human-clinical-trial 2025-06-04T09:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/abl-diagnostics-unveils-advanced-hiv-drug-resistance-detection-platform-at-european-meeting 2025-06-04T08:59:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abl-diagnostics-unveils-advanced-hiv-drug-resistance-detection-platform-at-european-meeting 2025-06-04T08:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/synact-pharma-secures-sek-30-million-credit-facility-to-advance-rheumatoid-arthritis-drug-development-through-mid-2026 2025-06-04T08:59:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synact-pharma-secures-sek-30-million-credit-facility-to-advance-rheumatoid-arthritis-drug-development-through-mid-2026 2025-06-04T08:59:52+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-clinical-trial-targets-treatment-resistant-ibs-in-groundbreaking-gastroenterology-study 2025-06-04T06:54:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psilocybin-clinical-trial-targets-treatment-resistant-ibs-in-groundbreaking-gastroenterology-study 2025-06-04T06:54:58+00:00 hourly 0.9 https://trial.medpath.com/news/akadeum-life-sciences-secures-20m-to-advance-cell-separation-technology-for-gene-and-cell-therapy-manufacturing 2025-06-04T04:57:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akadeum-life-sciences-secures-20m-to-advance-cell-separation-technology-for-gene-and-cell-therapy-manufacturing 2025-06-04T04:57:09+00:00 hourly 0.9 https://trial.medpath.com/news/transpire-bio-licenses-pde4-inhibitor-itg-1052-for-idiopathic-pulmonary-fibrosis-treatment 2025-06-04T01:52:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transpire-bio-licenses-pde4-inhibitor-itg-1052-for-idiopathic-pulmonary-fibrosis-treatment 2025-06-04T01:52:40+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-promise-for-adjuvant-braf-mek-inhibitor-combination-in-high-risk-melanoma 2025-06-04T00:58:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-shows-promise-for-adjuvant-braf-mek-inhibitor-combination-in-high-risk-melanoma 2025-06-04T00:58:58+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-immunotherapy-shows-unprecedented-five-year-survival-in-advanced-multiple-myeloma-patients 2025-06-04T00:58:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-immunotherapy-shows-unprecedented-five-year-survival-in-advanced-multiple-myeloma-patients 2025-06-04T00:58:47+00:00 hourly 0.9 https://trial.medpath.com/news/computer-modeling-identifies-two-broad-spectrum-antiviral-compounds-against-rna-viruses 2025-06-04T00:57:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/computer-modeling-identifies-two-broad-spectrum-antiviral-compounds-against-rna-viruses 2025-06-04T00:57:59+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-pharmaceutical-advances-phase-2-trial-of-novel-ipf-drug-bersiporocin-with-diverse-patient-population 2025-06-04T00:57:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daewoong-pharmaceutical-advances-phase-2-trial-of-novel-ipf-drug-bersiporocin-with-diverse-patient-population 2025-06-04T00:57:51+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-agrees-to-placebo-controlled-trial-for-new-covid-19-vaccine-following-fda-approval 2025-06-04T00:57:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-agrees-to-placebo-controlled-trial-for-new-covid-19-vaccine-following-fda-approval 2025-06-04T00:57:44+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-tumor-dna-emerges-as-powerful-prognostic-biomarker-in-locally-advanced-cervical-cancer 2025-06-04T00:56:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circulating-tumor-dna-emerges-as-powerful-prognostic-biomarker-in-locally-advanced-cervical-cancer 2025-06-04T00:56:17+00:00 hourly 0.9 https://trial.medpath.com/news/asco-2025-showcases-advances-in-myelofibrosis-treatment-with-novel-jak-inhibitors-and-personalized-approaches 2025-06-04T00:56:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asco-2025-showcases-advances-in-myelofibrosis-treatment-with-novel-jak-inhibitors-and-personalized-approaches 2025-06-04T00:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/essential-thrombocythemia-market-set-for-significant-growth-as-novel-therapies-enter-pipeline 2025-06-04T00:56:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essential-thrombocythemia-market-set-for-significant-growth-as-novel-therapies-enter-pipeline 2025-06-04T00:56:10+00:00 hourly 0.9 https://trial.medpath.com/news/ascletis-first-in-class-acne-drug-denifanstat-meets-all-phase-iii-endpoints-outperforms-fda-approved-treatments 2025-06-04T00:52:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascletis-first-in-class-acne-drug-denifanstat-meets-all-phase-iii-endpoints-outperforms-fda-approved-treatments 2025-06-04T00:52:56+00:00 hourly 0.9 https://trial.medpath.com/news/redwire-secures-contract-with-aspera-biomedicines-for-space-based-cancer-research-using-adar1-inhibitor-rebecsinib 2025-06-04T00:52:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redwire-secures-contract-with-aspera-biomedicines-for-space-based-cancer-research-using-adar1-inhibitor-rebecsinib 2025-06-04T00:52:24+00:00 hourly 0.9 https://trial.medpath.com/news/aravax-strengthens-leadership-team-with-regulatory-expert-louise-peacock-ahead-of-phase-3-peanut-allergy-trial 2025-06-03T22:55:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aravax-strengthens-leadership-team-with-regulatory-expert-louise-peacock-ahead-of-phase-3-peanut-allergy-trial 2025-06-03T22:55:51+00:00 hourly 0.9 https://trial.medpath.com/news/camurus-and-eli-lilly-forge-870-million-partnership-for-long-acting-diabetes-and-obesity-therapies 2025-06-03T21:54:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camurus-and-eli-lilly-forge-870-million-partnership-for-long-acting-diabetes-and-obesity-therapies 2025-06-03T21:54:11+00:00 hourly 0.9 https://trial.medpath.com/news/congruence-therapeutics-advances-cgx-926-for-rare-genetic-obesity-as-company-presents-novel-mc4r-corrector-data 2025-06-03T21:51:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/congruence-therapeutics-advances-cgx-926-for-rare-genetic-obesity-as-company-presents-novel-mc4r-corrector-data 2025-06-03T21:51:32+00:00 hourly 0.9 https://trial.medpath.com/news/quidelortho-pivots-molecular-diagnostics-strategy-with-100m-lex-diagnostics-acquisition 2025-06-03T21:03:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quidelortho-pivots-molecular-diagnostics-strategy-with-100m-lex-diagnostics-acquisition 2025-06-03T21:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/us-court-allows-lupin-and-zydus-to-expand-patent-defense-arguments-in-myrbetriq-generic-drug-case 2025-06-03T20:59:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-court-allows-lupin-and-zydus-to-expand-patent-defense-arguments-in-myrbetriq-generic-drug-case 2025-06-03T20:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/dante-trial-shows-promise-for-shorter-immunotherapy-duration-in-advanced-melanoma 2025-06-03T20:59:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dante-trial-shows-promise-for-shorter-immunotherapy-duration-in-advanced-melanoma 2025-06-03T20:59:44+00:00 hourly 0.9 https://trial.medpath.com/news/huntington-s-disease-pipeline-shows-robust-growth-with-20-companies-developing-novel-therapies 2025-06-03T20:57:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huntington-s-disease-pipeline-shows-robust-growth-with-20-companies-developing-novel-therapies 2025-06-03T20:57:34+00:00 hourly 0.9 https://trial.medpath.com/news/aspaveli-demonstrates-sustained-68-proteinuria-reduction-in-phase-3-valiant-trial-for-rare-kidney-diseases 2025-06-03T20:57:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspaveli-demonstrates-sustained-68-proteinuria-reduction-in-phase-3-valiant-trial-for-rare-kidney-diseases 2025-06-03T20:57:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-darolutamide-for-metastatic-castration-sensitive-prostate-cancer-based-on-aranote-trial-results 2025-06-03T20:53:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-darolutamide-for-metastatic-castration-sensitive-prostate-cancer-based-on-aranote-trial-results 2025-06-03T20:53:15+00:00 hourly 0.9 https://trial.medpath.com/news/leyden-labs-secures-eur20-million-eib-funding-to-advance-pan-influenza-nasal-spray-development 2025-06-03T19:51:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leyden-labs-secures-eur20-million-eib-funding-to-advance-pan-influenza-nasal-spray-development 2025-06-03T19:51:41+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-launches-phase-2a-trial-of-delgocitinib-cream-for-rare-skin-disease-palmoplantar-pustulosis 2025-06-03T18:53:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-launches-phase-2a-trial-of-delgocitinib-cream-for-rare-skin-disease-palmoplantar-pustulosis 2025-06-03T18:53:49+00:00 hourly 0.9 https://trial.medpath.com/news/brain-training-game-shows-promise-for-drug-free-nerve-pain-treatment-in-first-clinical-trial 2025-06-03T18:51:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-training-game-shows-promise-for-drug-free-nerve-pain-treatment-in-first-clinical-trial 2025-06-03T18:51:52+00:00 hourly 0.9 https://trial.medpath.com/news/affinia-therapeutics-partners-with-dcm-foundation-to-advance-bag3-dilated-cardiomyopathy-awareness-and-genetic-testing 2025-06-03T18:51:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affinia-therapeutics-partners-with-dcm-foundation-to-advance-bag3-dilated-cardiomyopathy-awareness-and-genetic-testing 2025-06-03T18:51:15+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-to-present-briquilimab-clinical-data-at-eaaci-congress-2025 2025-06-03T17:04:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jasper-therapeutics-to-present-briquilimab-clinical-data-at-eaaci-congress-2025 2025-06-03T17:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-secures-exclusive-rights-to-agenus-bot-bal-cancer-immunotherapy-for-india-and-sri-lanka 2025-06-03T17:04:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-secures-exclusive-rights-to-agenus-bot-bal-cancer-immunotherapy-for-india-and-sri-lanka 2025-06-03T17:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/antheia-secures-56m-series-c-to-scale-synthetic-biology-platform-for-critical-drug-manufacturing 2025-06-03T17:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antheia-secures-56m-series-c-to-scale-synthetic-biology-platform-for-critical-drug-manufacturing 2025-06-03T17:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-discontinues-psoriasis-and-eczema-drug-scd-044-after-phase-2-trial-failures 2025-06-03T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-discontinues-psoriasis-and-eczema-drug-scd-044-after-phase-2-trial-failures 2025-06-03T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/russia-s-personalized-mrna-cancer-vaccine-set-for-clinical-launch-by-october-2025 2025-06-03T17:03:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/russia-s-personalized-mrna-cancer-vaccine-set-for-clinical-launch-by-october-2025 2025-06-03T17:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/allergan-botox-patent-infringement-trial-against-revance-set-for-july-in-delaware 2025-06-03T17:03:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allergan-botox-patent-infringement-trial-against-revance-set-for-july-in-delaware 2025-06-03T17:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/patent-trial-and-appeal-board-institutes-review-against-halozyme-in-merck-patent-dispute 2025-06-03T17:03:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patent-trial-and-appeal-board-institutes-review-against-halozyme-in-merck-patent-dispute 2025-06-03T17:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/trexbio-initiates-first-in-human-trial-of-trb-061-novel-tnfr2-agonist-for-atopic-dermatitis 2025-06-03T17:02:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trexbio-initiates-first-in-human-trial-of-trb-061-novel-tnfr2-agonist-for-atopic-dermatitis 2025-06-03T17:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/ocu410-gene-therapy-shows-promise-for-geographic-atrophy-with-single-dose-treatment-approach 2025-06-03T17:00:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocu410-gene-therapy-shows-promise-for-geographic-atrophy-with-single-dose-treatment-approach 2025-06-03T17:00:52+00:00 hourly 0.9 https://trial.medpath.com/news/mentaily-secures-3m-seed-funding-for-ai-powered-mental-health-diagnostic-platform-liv 2025-06-03T17:00:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mentaily-secures-3m-seed-funding-for-ai-powered-mental-health-diagnostic-platform-liv 2025-06-03T17:00:46+00:00 hourly 0.9 https://trial.medpath.com/news/vera-therapeutics-secures-500-million-credit-facility-to-support-atacicept-commercial-launch 2025-06-03T17:00:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vera-therapeutics-secures-500-million-credit-facility-to-support-atacicept-commercial-launch 2025-06-03T17:00:10+00:00 hourly 0.9 https://trial.medpath.com/news/bioage-expands-apj-agonist-pipeline-with-novel-oral-and-injectable-candidates-for-enhanced-obesity-treatment 2025-06-03T16:59:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioage-expands-apj-agonist-pipeline-with-novel-oral-and-injectable-candidates-for-enhanced-obesity-treatment 2025-06-03T16:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/reshape-lifesciences-achieves-early-eu-mdr-certification-for-obesity-treatment-devices 2025-06-03T16:59:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reshape-lifesciences-achieves-early-eu-mdr-certification-for-obesity-treatment-devices 2025-06-03T16:59:01+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-receives-fda-orphan-drug-designation-for-beam-101-sickle-cell-disease-therapy 2025-06-03T16:58:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beam-therapeutics-receives-fda-orphan-drug-designation-for-beam-101-sickle-cell-disease-therapy 2025-06-03T16:58:59+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-temab-a-adc-shows-63-response-rate-in-egfr-mutated-nsclc-phase-i-trial 2025-06-03T16:56:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-temab-a-adc-shows-63-response-rate-in-egfr-mutated-nsclc-phase-i-trial 2025-06-03T16:56:29+00:00 hourly 0.9 https://trial.medpath.com/news/amplitude-trial-shows-niraparib-combination-reduces-cancer-progression-risk-by-37-in-hrr-mutant-metastatic-prostate-cancer 2025-06-03T16:54:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amplitude-trial-shows-niraparib-combination-reduces-cancer-progression-risk-by-37-in-hrr-mutant-metastatic-prostate-cancer 2025-06-03T16:54:14+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-sarclisa-shows-non-inferior-efficacy-with-novel-on-body-injector-in-phase-3-multiple-myeloma-trial 2025-06-03T15:52:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-sarclisa-shows-non-inferior-efficacy-with-novel-on-body-injector-in-phase-3-multiple-myeloma-trial 2025-06-03T15:52:41+00:00 hourly 0.9 https://trial.medpath.com/news/matter-neuroscience-partners-with-stanford-medicine-to-test-novel-fmri-guided-depression-therapy 2025-06-03T13:51:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matter-neuroscience-partners-with-stanford-medicine-to-test-novel-fmri-guided-depression-therapy 2025-06-03T13:51:09+00:00 hourly 0.9 https://trial.medpath.com/news/catalyst-pharmaceuticals-appoints-dr-william-andrews-as-chief-medical-officer-to-lead-rare-disease-strategy 2025-06-03T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalyst-pharmaceuticals-appoints-dr-william-andrews-as-chief-medical-officer-to-lead-rare-disease-strategy 2025-06-03T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/flot-chemotherapy-demonstrates-superior-survival-and-distant-recurrence-control-over-cross-in-esophageal-adenocarcinoma 2025-06-03T13:48:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flot-chemotherapy-demonstrates-superior-survival-and-distant-recurrence-control-over-cross-in-esophageal-adenocarcinoma 2025-06-03T13:48:11+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-trans-amplifying-mrna-vaccine-platform-with-40-fold-dose-reduction-and-broad-viral-protection 2025-06-03T12:57:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-develop-trans-amplifying-mrna-vaccine-platform-with-40-fold-dose-reduction-and-broad-viral-protection 2025-06-03T12:57:12+00:00 hourly 0.9 https://trial.medpath.com/news/minerva-biotechnologies-advances-muc1-targeted-car-t-therapy-with-1xx-mutations-for-solid-tumors 2025-06-03T12:56:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minerva-biotechnologies-advances-muc1-targeted-car-t-therapy-with-1xx-mutations-for-solid-tumors 2025-06-03T12:56:43+00:00 hourly 0.9 https://trial.medpath.com/news/kamari-pharma-secures-23-million-series-a-to-advance-first-in-class-trpv3-inhibitor-for-rare-genetic-skin-diseases 2025-06-03T12:55:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kamari-pharma-secures-23-million-series-a-to-advance-first-in-class-trpv3-inhibitor-for-rare-genetic-skin-diseases 2025-06-03T12:55:49+00:00 hourly 0.9 https://trial.medpath.com/news/rigosertib-achieves-80-response-rate-in-first-clinical-trial-for-rare-rdeb-associated-skin-cancer 2025-06-03T12:55:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigosertib-achieves-80-response-rate-in-first-clinical-trial-for-rare-rdeb-associated-skin-cancer 2025-06-03T12:55:11+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-researchers-launch-final-phase-trial-of-bromocriptine-for-familial-alzheimer-s-disease 2025-06-03T12:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-researchers-launch-final-phase-trial-of-bromocriptine-for-familial-alzheimer-s-disease 2025-06-03T12:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/markherz-partners-with-tum-hospital-to-advance-aav-gene-therapy-for-cardiovascular-disease 2025-06-03T12:53:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/markherz-partners-with-tum-hospital-to-advance-aav-gene-therapy-for-cardiovascular-disease 2025-06-03T12:53:55+00:00 hourly 0.9 https://trial.medpath.com/news/spago-nanomedical-s-radioligand-therapy-177lu-sn201-advances-in-phase-i-iia-trial-following-positive-safety-review 2025-06-03T12:53:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spago-nanomedical-s-radioligand-therapy-177lu-sn201-advances-in-phase-i-iia-trial-following-positive-safety-review 2025-06-03T12:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-receives-cdsco-approval-for-liraglutide-diabetes-drug-in-india 2025-06-03T09:01:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-receives-cdsco-approval-for-liraglutide-diabetes-drug-in-india 2025-06-03T09:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/jade-biosciences-to-present-preclinical-data-on-jade101-anti-april-antibody-for-iga-nephropathy-at-european-renal-congress 2025-06-03T08:55:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jade-biosciences-to-present-preclinical-data-on-jade101-anti-april-antibody-for-iga-nephropathy-at-european-renal-congress 2025-06-03T08:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/nutriband-advances-aversa-fentanyl-abuse-deterrent-patch-development-with-kindeva-partnership 2025-06-03T07:56:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutriband-advances-aversa-fentanyl-abuse-deterrent-patch-development-with-kindeva-partnership 2025-06-03T07:56:07+00:00 hourly 0.9 https://trial.medpath.com/news/spyglass-pharma-secures-75-million-series-d-to-advance-long-term-glaucoma-drug-delivery-platform-through-phase-iii-trials 2025-06-03T06:54:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spyglass-pharma-secures-75-million-series-d-to-advance-long-term-glaucoma-drug-delivery-platform-through-phase-iii-trials 2025-06-03T06:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/sony-screen-and-vitrovo-launch-high-density-mea-system-trial-for-drug-discovery-and-neurological-disease-research 2025-06-03T05:52:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sony-screen-and-vitrovo-launch-high-density-mea-system-trial-for-drug-discovery-and-neurological-disease-research 2025-06-03T05:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/terbium-161-radioimmunotherapy-shows-superior-efficacy-against-lymphoma-in-preclinical-studies 2025-06-03T04:55:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terbium-161-radioimmunotherapy-shows-superior-efficacy-against-lymphoma-in-preclinical-studies 2025-06-03T04:55:11+00:00 hourly 0.9 https://trial.medpath.com/news/amivantamab-shows-promise-in-colorectal-cancer-as-phase-3-trials-launch-following-encouraging-phase-1b-2-results 2025-06-03T04:51:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amivantamab-shows-promise-in-colorectal-cancer-as-phase-3-trials-launch-following-encouraging-phase-1b-2-results 2025-06-03T04:51:45+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-biomarker-and-prognostic-framework-emerges-for-attr-cm-disease-monitoring 2025-06-03T02:52:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-biomarker-and-prognostic-framework-emerges-for-attr-cm-disease-monitoring 2025-06-03T02:52:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-authorization-for-ai-platform-to-predict-breast-cancer-risk-from-mammograms 2025-06-03T01:51:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-ever-authorization-for-ai-platform-to-predict-breast-cancer-risk-from-mammograms 2025-06-03T01:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-partners-with-foresight-diagnostics-and-tracer-biotechnologies-to-expand-minimal-residual-disease-testing-portfolio 2025-06-03T01:50:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qiagen-partners-with-foresight-diagnostics-and-tracer-biotechnologies-to-expand-minimal-residual-disease-testing-portfolio 2025-06-03T01:50:45+00:00 hourly 0.9 https://trial.medpath.com/news/trastuzumab-deruxtecan-combination-reduces-disease-progression-risk-by-44-in-her2-positive-metastatic-breast-cancer 2025-06-03T00:58:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trastuzumab-deruxtecan-combination-reduces-disease-progression-risk-by-44-in-her2-positive-metastatic-breast-cancer 2025-06-03T00:58:31+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-belantamab-mafodotin-maintains-efficacy-in-high-risk-multiple-myeloma-patients-despite-treatment-withdrawal 2025-06-03T00:57:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-belantamab-mafodotin-maintains-efficacy-in-high-risk-multiple-myeloma-patients-despite-treatment-withdrawal 2025-06-03T00:57:19+00:00 hourly 0.9 https://trial.medpath.com/news/extended-low-dose-apixaban-reduces-vte-recurrence-by-87-in-high-risk-patients 2025-06-03T00:55:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-low-dose-apixaban-reduces-vte-recurrence-by-87-in-high-risk-patients 2025-06-03T00:55:23+00:00 hourly 0.9 https://trial.medpath.com/news/immuneoncia-s-cd47-antibody-imc-002-shows-30-response-rate-in-advanced-hepatocellular-carcinoma-trial 2025-06-03T00:55:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneoncia-s-cd47-antibody-imc-002-shows-30-response-rate-in-advanced-hepatocellular-carcinoma-trial 2025-06-03T00:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/merck-explores-3-billion-acquisition-of-swiss-biotech-moonlake-immunotherapeutics 2025-06-03T00:53:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-explores-3-billion-acquisition-of-swiss-biotech-moonlake-immunotherapeutics 2025-06-03T00:53:03+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-and-beckley-psytech-announce-390-million-merger-to-create-psychedelic-mental-health-leader 2025-06-03T00:52:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atai-life-sciences-and-beckley-psytech-announce-390-million-merger-to-create-psychedelic-mental-health-leader 2025-06-03T00:52:34+00:00 hourly 0.9 https://trial.medpath.com/news/novel-antibody-drug-conjugate-achieves-85-response-rate-in-rare-blood-cancer-trial 2025-06-03T00:50:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-antibody-drug-conjugate-achieves-85-response-rate-in-rare-blood-cancer-trial 2025-06-03T00:50:31+00:00 hourly 0.9 https://trial.medpath.com/news/allogeneic-cell-therapies-emerge-as-next-generation-cancer-treatment-to-address-manufacturing-and-cost-challenges 2025-06-03T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allogeneic-cell-therapies-emerge-as-next-generation-cancer-treatment-to-address-manufacturing-and-cost-challenges 2025-06-03T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/jenscare-reports-positive-clinical-outcomes-for-tricuspid-and-mitral-valve-interventions-at-europcr-2025 2025-06-03T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jenscare-reports-positive-clinical-outcomes-for-tricuspid-and-mitral-valve-interventions-at-europcr-2025 2025-06-03T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-submits-low-dose-mri-contrast-agent-gadoquatrane-for-global-regulatory-approval 2025-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-submits-low-dose-mri-contrast-agent-gadoquatrane-for-global-regulatory-approval 2025-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/freenome-s-blood-based-colorectal-cancer-test-achieves-landmark-results-in-largest-prospective-study 2025-06-02T23:52:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/freenome-s-blood-based-colorectal-cancer-test-achieves-landmark-results-in-largest-prospective-study 2025-06-02T23:52:12+00:00 hourly 0.9 https://trial.medpath.com/news/biocartis-achieves-first-ivdr-class-c-companion-diagnostic-certification-for-egfr-mutation-test-in-europe 2025-06-02T22:54:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocartis-achieves-first-ivdr-class-c-companion-diagnostic-certification-for-egfr-mutation-test-in-europe 2025-06-02T22:54:10+00:00 hourly 0.9 https://trial.medpath.com/news/vantive-announces-1-billion-investment-in-digital-kidney-care-technologies-over-five-years 2025-06-02T22:53:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vantive-announces-1-billion-investment-in-digital-kidney-care-technologies-over-five-years 2025-06-02T22:53:24+00:00 hourly 0.9 https://trial.medpath.com/news/rly-2608-shows-promise-in-pik3ca-mutant-breast-cancer-with-improved-tolerability-profile 2025-06-02T21:53:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rly-2608-shows-promise-in-pik3ca-mutant-breast-cancer-with-improved-tolerability-profile 2025-06-02T21:53:51+00:00 hourly 0.9 https://trial.medpath.com/news/curogen-appoints-industry-veteran-arvind-sood-as-global-coo-to-lead-us-expansion-of-nanotechnology-based-autoimmune-therapies 2025-06-02T21:50:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curogen-appoints-industry-veteran-arvind-sood-as-global-coo-to-lead-us-expansion-of-nanotechnology-based-autoimmune-therapies 2025-06-02T21:50:44+00:00 hourly 0.9 https://trial.medpath.com/news/protara-therapeutics-appoints-william-conkling-as-chief-commercial-officer-to-lead-commercialization-strategy 2025-06-02T21:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protara-therapeutics-appoints-william-conkling-as-chief-commercial-officer-to-lead-commercialization-strategy 2025-06-02T21:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-data-show-lasting-survival-benefits-from-single-dose-til-therapy-in-advanced-melanoma 2025-06-02T21:03:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-year-data-show-lasting-survival-benefits-from-single-dose-til-therapy-in-advanced-melanoma 2025-06-02T21:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-high-throughput-lectin-based-screening-method-to-optimize-sialic-acid-glycosylation-in-drug-development 2025-06-02T20:58:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-develop-high-throughput-lectin-based-screening-method-to-optimize-sialic-acid-glycosylation-in-drug-development 2025-06-02T20:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/frontage-laboratories-expands-manufacturing-capabilities-with-new-46300-sq-ft-crdmo-facility-in-pennsylvania 2025-06-02T20:56:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frontage-laboratories-expands-manufacturing-capabilities-with-new-46300-sq-ft-crdmo-facility-in-pennsylvania 2025-06-02T20:56:43+00:00 hourly 0.9 https://trial.medpath.com/news/rebecsinib-becomes-first-space-tested-cancer-drug-to-enter-clinical-trials 2025-06-02T20:56:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rebecsinib-becomes-first-space-tested-cancer-drug-to-enter-clinical-trials 2025-06-02T20:56:24+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-s-lenvima-combination-therapy-receives-chinese-approval-for-unresectable-hepatocellular-carcinoma 2025-06-02T19:53:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-s-lenvima-combination-therapy-receives-chinese-approval-for-unresectable-hepatocellular-carcinoma 2025-06-02T19:53:43+00:00 hourly 0.9 https://trial.medpath.com/news/berkshire-biomedical-secures-2-9m-nih-grant-for-biometric-methadone-dispensing-system-clinical-study 2025-06-02T17:54:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/berkshire-biomedical-secures-2-9m-nih-grant-for-biometric-methadone-dispensing-system-clinical-study 2025-06-02T17:54:07+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-reports-positive-phase-2-data-for-eo2463-in-indolent-non-hodgkin-lymphoma 2025-06-02T17:53:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterome-reports-positive-phase-2-data-for-eo2463-in-indolent-non-hodgkin-lymphoma 2025-06-02T17:53:44+00:00 hourly 0.9 https://trial.medpath.com/news/culturally-tailored-intervention-shows-promise-for-latina-breast-cancer-survivors-in-randomized-trial 2025-06-02T17:52:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/culturally-tailored-intervention-shows-promise-for-latina-breast-cancer-survivors-in-randomized-trial 2025-06-02T17:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-presents-comprehensive-serplulimab-data-at-asco-2025-demonstrating-broad-efficacy-across-multiple-cancer-types 2025-06-02T17:52:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-presents-comprehensive-serplulimab-data-at-asco-2025-demonstrating-broad-efficacy-across-multiple-cancer-types 2025-06-02T17:52:04+00:00 hourly 0.9 https://trial.medpath.com/news/sbrt-addition-to-nivolumab-ipilimumab-fails-to-improve-outcomes-in-metastatic-castration-resistant-prostate-cancer 2025-06-02T17:51:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sbrt-addition-to-nivolumab-ipilimumab-fails-to-improve-outcomes-in-metastatic-castration-resistant-prostate-cancer 2025-06-02T17:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-launches-first-in-human-trial-of-aro-alk7-for-obesity-treatment 2025-06-02T17:50:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-launches-first-in-human-trial-of-aro-alk7-for-obesity-treatment 2025-06-02T17:50:41+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-trevogrumab-shows-promise-in-preserving-muscle-mass-when-combined-with-wegovy-in-weight-loss-study 2025-06-02T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-s-trevogrumab-shows-promise-in-preserving-muscle-mass-when-combined-with-wegovy-in-weight-loss-study 2025-06-02T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/oncusp-s-cdh6-directed-adc-cusp06-shows-36-response-rate-in-platinum-resistant-ovarian-cancer 2025-06-02T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncusp-s-cdh6-directed-adc-cusp06-shows-36-response-rate-in-platinum-resistant-ovarian-cancer 2025-06-02T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/kivu-bioscience-partners-with-sterling-pharma-for-phase-1-manufacturing-of-next-generation-adc-kivu-107 2025-06-02T17:03:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kivu-bioscience-partners-with-sterling-pharma-for-phase-1-manufacturing-of-next-generation-adc-kivu-107 2025-06-02T17:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/newcastle-university-researchers-identify-novel-cd30-targeting-combination-therapy-to-overcome-immune-checkpoint-blockade-resistance-in-melanoma 2025-06-02T17:03:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newcastle-university-researchers-identify-novel-cd30-targeting-combination-therapy-to-overcome-immune-checkpoint-blockade-resistance-in-melanoma 2025-06-02T17:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-secures-niaid-grant-to-develop-inkt-cell-therapy-for-graft-versus-host-disease-prevention 2025-06-02T17:02:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mink-therapeutics-secures-niaid-grant-to-develop-inkt-cell-therapy-for-graft-versus-host-disease-prevention 2025-06-02T17:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-receives-indian-regulatory-approval-for-generic-liraglutide-expanding-glp-1-diabetes-treatment-access 2025-06-02T17:02:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-receives-indian-regulatory-approval-for-generic-liraglutide-expanding-glp-1-diabetes-treatment-access 2025-06-02T17:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-licenses-chinese-glp-1-gip-dual-agonist-in-2-billion-obesity-deal-with-hansoh-pharma 2025-06-02T17:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-licenses-chinese-glp-1-gip-dual-agonist-in-2-billion-obesity-deal-with-hansoh-pharma 2025-06-02T17:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-monoclonal-antibody-therapy-shows-promise-against-mugwort-pollen-allergy-in-preclinical-study 2025-06-02T17:01:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intranasal-monoclonal-antibody-therapy-shows-promise-against-mugwort-pollen-allergy-in-preclinical-study 2025-06-02T17:01:51+00:00 hourly 0.9 https://trial.medpath.com/news/china-patent-board-upholds-rnai-therapeutic-patents-despite-broad-claim-challenges 2025-06-02T17:01:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-patent-board-upholds-rnai-therapeutic-patents-despite-broad-claim-challenges 2025-06-02T17:01:15+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-secures-key-patent-for-il-2-liquid-formulation-advances-als-combination-therapy 2025-06-02T17:01:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coya-therapeutics-secures-key-patent-for-il-2-liquid-formulation-advances-als-combination-therapy 2025-06-02T17:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-nivolumab-plus-chemotherapy-demonstrates-10-survival-advantage-in-resectable-nsclc-at-5-year-follow-up 2025-06-02T17:01:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-nivolumab-plus-chemotherapy-demonstrates-10-survival-advantage-in-resectable-nsclc-at-5-year-follow-up 2025-06-02T17:01:04+00:00 hourly 0.9 https://trial.medpath.com/news/dll3-targeted-car-t-therapy-lb2102-shows-promise-in-relapsed-refractory-small-cell-lung-cancer 2025-06-02T17:01:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dll3-targeted-car-t-therapy-lb2102-shows-promise-in-relapsed-refractory-small-cell-lung-cancer 2025-06-02T17:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/sutro-biopharma-appoints-greg-chow-as-cfo-to-advance-adc-pipeline 2025-06-02T16:59:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sutro-biopharma-appoints-greg-chow-as-cfo-to-advance-adc-pipeline 2025-06-02T16:59:16+00:00 hourly 0.9 https://trial.medpath.com/news/instil-bio-appoints-veteran-oncologist-jamie-freedman-as-chief-medical-officer-to-advance-pd-l1xvegf-bispecific 2025-06-02T16:59:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/instil-bio-appoints-veteran-oncologist-jamie-freedman-as-chief-medical-officer-to-advance-pd-l1xvegf-bispecific 2025-06-02T16:59:14+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-next-generation-adc-shows-55-response-rate-in-platinum-resistant-ovarian-cancer 2025-06-02T16:59:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-next-generation-adc-shows-55-response-rate-in-platinum-resistant-ovarian-cancer 2025-06-02T16:59:09+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-cancer-biomarkers-partners-with-mira-precision-health-to-advance-toxnav-r-test-for-5fu-capecitabine-toxicity-prediction-in-us-market 2025-06-02T16:59:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-cancer-biomarkers-partners-with-mira-precision-health-to-advance-toxnav-r-test-for-5fu-capecitabine-toxicity-prediction-in-us-market 2025-06-02T16:59:07+00:00 hourly 0.9 https://trial.medpath.com/news/swog-s2302-pragmatica-lung-trial-fails-to-show-survival-benefit-but-sets-new-standard-for-streamlined-cancer-research 2025-06-02T16:56:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swog-s2302-pragmatica-lung-trial-fails-to-show-survival-benefit-but-sets-new-standard-for-streamlined-cancer-research 2025-06-02T16:56:05+00:00 hourly 0.9 https://trial.medpath.com/news/dyadic-international-appoints-joe-hazelton-as-president-to-lead-strategic-pivot-to-ancillary-protein-markets 2025-06-02T16:55:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyadic-international-appoints-joe-hazelton-as-president-to-lead-strategic-pivot-to-ancillary-protein-markets 2025-06-02T16:55:56+00:00 hourly 0.9 https://trial.medpath.com/news/viz-ai-partners-with-novartis-to-develop-ai-powered-cancer-care-solutions-for-prostate-and-breast-cancer 2025-06-02T16:55:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viz-ai-partners-with-novartis-to-develop-ai-powered-cancer-care-solutions-for-prostate-and-breast-cancer 2025-06-02T16:55:54+00:00 hourly 0.9 https://trial.medpath.com/news/outlook-therapeutics-launches-first-approved-ophthalmic-bevacizumab-in-europe-for-wet-amd-treatment 2025-06-02T16:55:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outlook-therapeutics-launches-first-approved-ophthalmic-bevacizumab-in-europe-for-wet-amd-treatment 2025-06-02T16:55:50+00:00 hourly 0.9 https://trial.medpath.com/news/vera-therapeutics-atacicept-achieves-46-proteinuria-reduction-in-phase-3-iga-nephropathy-trial 2025-06-02T16:55:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vera-therapeutics-atacicept-achieves-46-proteinuria-reduction-in-phase-3-iga-nephropathy-trial 2025-06-02T16:55:41+00:00 hourly 0.9 https://trial.medpath.com/news/danhong-injection-shows-promise-in-reducing-inflammation-and-improving-vascular-function-in-unstable-angina-patients 2025-06-02T16:55:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/danhong-injection-shows-promise-in-reducing-inflammation-and-improving-vascular-function-in-unstable-angina-patients 2025-06-02T16:55:37+00:00 hourly 0.9 https://trial.medpath.com/news/evosep-launches-high-throughput-proteomics-platform-eno-and-expands-sciex-partnership-at-asms-2025 2025-06-02T16:54:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evosep-launches-high-throughput-proteomics-platform-eno-and-expands-sciex-partnership-at-asms-2025 2025-06-02T16:54:44+00:00 hourly 0.9 https://trial.medpath.com/news/stemcell-technologies-acquires-cellular-highways-to-advance-cell-therapy-manufacturing-with-revolutionary-vacs-technology 2025-06-02T16:53:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stemcell-technologies-acquires-cellular-highways-to-advance-cell-therapy-manufacturing-with-revolutionary-vacs-technology 2025-06-02T16:53:33+00:00 hourly 0.9 https://trial.medpath.com/news/4d-path-s-digital-biomarker-identifies-treatment-responders-in-previously-resistant-breast-cancer-patients 2025-06-02T16:53:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4d-path-s-digital-biomarker-identifies-treatment-responders-in-previously-resistant-breast-cancer-patients 2025-06-02T16:53:15+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-and-biontech-submit-ema-application-for-updated-covid-19-vaccine-targeting-lp-8-1-strain-for-2025-2026-season 2025-06-02T16:53:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-and-biontech-submit-ema-application-for-updated-covid-19-vaccine-targeting-lp-8-1-strain-for-2025-2026-season 2025-06-02T16:53:07+00:00 hourly 0.9 https://trial.medpath.com/news/ibudilast-fails-to-show-efficacy-for-alcohol-use-disorder-in-phase-2-trial-but-shows-promise-for-women 2025-06-02T16:52:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibudilast-fails-to-show-efficacy-for-alcohol-use-disorder-in-phase-2-trial-but-shows-promise-for-women 2025-06-02T16:52:39+00:00 hourly 0.9 https://trial.medpath.com/news/vistagen-advances-fasedienol-phase-3-program-for-social-anxiety-disorder-with-q4-2025-data-readout 2025-06-02T16:52:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vistagen-advances-fasedienol-phase-3-program-for-social-anxiety-disorder-with-q4-2025-data-readout 2025-06-02T16:52:05+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-immunotherapy-response-in-rare-lung-adenosquamous-carcinoma-with-multiple-driver-mutations 2025-06-02T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-immunotherapy-response-in-rare-lung-adenosquamous-carcinoma-with-multiple-driver-mutations 2025-06-02T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ferroptosis-emerges-as-novel-therapeutic-target-in-cancer-treatment-and-immunotherapy 2025-06-02T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ferroptosis-emerges-as-novel-therapeutic-target-in-cancer-treatment-and-immunotherapy 2025-06-02T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunabs-receives-fda-clearance-for-phase-2-trial-of-im-101-complement-inhibitor-in-myasthenia-gravis 2025-06-02T13:52:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunabs-receives-fda-clearance-for-phase-2-trial-of-im-101-complement-inhibitor-in-myasthenia-gravis 2025-06-02T13:52:34+00:00 hourly 0.9 https://trial.medpath.com/news/alneo-trial-demonstrates-promising-perioperative-alectinib-activity-in-stage-iii-alk-positive-nsclc 2025-06-02T13:52:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alneo-trial-demonstrates-promising-perioperative-alectinib-activity-in-stage-iii-alk-positive-nsclc 2025-06-02T13:52:08+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-reports-promising-early-data-for-two-novel-breast-cancer-therapies-at-asco-2025 2025-06-02T12:51:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beone-medicines-reports-promising-early-data-for-two-novel-breast-cancer-therapies-at-asco-2025 2025-06-02T12:51:24+00:00 hourly 0.9 https://trial.medpath.com/news/kalvista-s-sebetralstat-halts-hereditary-angioedema-attacks-in-median-19-8-minutes-across-clinical-trials 2025-06-02T12:50:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kalvista-s-sebetralstat-halts-hereditary-angioedema-attacks-in-median-19-8-minutes-across-clinical-trials 2025-06-02T12:50:30+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-partners-with-biontech-in-11-1-billion-deal-for-dual-target-cancer-immunotherapy 2025-06-02T12:49:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-partners-with-biontech-in-11-1-billion-deal-for-dual-target-cancer-immunotherapy 2025-06-02T12:49:46+00:00 hourly 0.9 https://trial.medpath.com/news/vera-therapeutics-atacicept-achieves-46-protein-reduction-in-phase-3-iga-nephropathy-trial 2025-06-02T12:49:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vera-therapeutics-atacicept-achieves-46-protein-reduction-in-phase-3-iga-nephropathy-trial 2025-06-02T12:49:37+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-reports-positive-phase-3-results-for-mr-142-in-treating-night-vision-disturbances-after-refractive-surgery 2025-06-02T12:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-reports-positive-phase-3-results-for-mr-142-in-treating-night-vision-disturbances-after-refractive-surgery 2025-06-02T12:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-establishes-first-u-s-laboratory-in-boston-cambridge-to-advance-adc-technology 2025-06-02T12:47:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/defence-therapeutics-establishes-first-u-s-laboratory-in-boston-cambridge-to-advance-adc-technology 2025-06-02T12:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-eli-lilly-s-mirikizumab-for-crohn-s-disease-treatment-following-positive-phase-3-trial-results 2025-06-02T12:20:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-recommends-eli-lilly-s-mirikizumab-for-crohn-s-disease-treatment-following-positive-phase-3-trial-results 2025-06-02T12:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/relay-therapeutics-reports-sustained-efficacy-for-rly-2608-in-pi3ka-mutated-breast-cancer-at-asco-2025 2025-06-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relay-therapeutics-reports-sustained-efficacy-for-rly-2608-in-pi3ka-mutated-breast-cancer-at-asco-2025 2025-06-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/terumo-neuro-launches-sofia-flow-88-neurovascular-aspiration-catheter-in-emea-markets 2025-06-02T10:54:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terumo-neuro-launches-sofia-flow-88-neurovascular-aspiration-catheter-in-emea-markets 2025-06-02T10:54:50+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-approves-serplulimab-as-first-anti-pd-1-therapy-for-small-cell-lung-cancer-in-uk 2025-06-02T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-approves-serplulimab-as-first-anti-pd-1-therapy-for-small-cell-lung-cancer-in-uk 2025-06-02T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/asp-isotopes-and-isotopia-forge-strategic-partnership-to-accelerate-terbium-161-cancer-therapy-production 2025-06-02T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asp-isotopes-and-isotopia-forge-strategic-partnership-to-accelerate-terbium-161-cancer-therapy-production 2025-06-02T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mixed-results-for-adjuvant-immunotherapy-in-high-risk-cutaneous-squamous-cell-carcinoma 2025-06-02T08:56:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mixed-results-for-adjuvant-immunotherapy-in-high-risk-cutaneous-squamous-cell-carcinoma 2025-06-02T08:56:01+00:00 hourly 0.9 https://trial.medpath.com/news/deepeye-medical-receives-ce-mark-for-ai-powered-therapy-planning-assistant-for-amd-treatment 2025-06-02T08:53:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepeye-medical-receives-ce-mark-for-ai-powered-therapy-planning-assistant-for-amd-treatment 2025-06-02T08:53:40+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-launches-first-interchangeable-denosumab-biosimilars-in-us-expanding-access-for-osteoporosis-and-cancer-patients 2025-06-02T08:52:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-launches-first-interchangeable-denosumab-biosimilars-in-us-expanding-access-for-osteoporosis-and-cancer-patients 2025-06-02T08:52:45+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-acquires-blueprint-medicines-for-9-1-billion-to-strengthen-rare-disease-and-immunology-portfolio 2025-06-02T08:52:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-acquires-blueprint-medicines-for-9-1-billion-to-strengthen-rare-disease-and-immunology-portfolio 2025-06-02T08:52:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-denies-approval-for-elamipretide-despite-dramatic-heart-function-improvements-in-barth-syndrome-patients 2025-06-02T08:52:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-denies-approval-for-elamipretide-despite-dramatic-heart-function-improvements-in-barth-syndrome-patients 2025-06-02T08:52:29+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-presents-promising-clinical-data-for-multiple-oncology-pipeline-candidates-at-major-medical-conferences 2025-06-02T05:52:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-presents-promising-clinical-data-for-multiple-oncology-pipeline-candidates-at-major-medical-conferences 2025-06-02T05:52:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-tightens-nitrosamine-testing-requirements-with-new-guidelines-taking-effect-this-august 2025-06-02T04:54:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-tightens-nitrosamine-testing-requirements-with-new-guidelines-taking-effect-this-august 2025-06-02T04:54:23+00:00 hourly 0.9 https://trial.medpath.com/news/j-ints-bio-s-fourth-generation-egfr-tki-jin-a02-shows-promising-anti-tumor-activity-in-resistant-nsclc-patients 2025-06-02T04:53:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-ints-bio-s-fourth-generation-egfr-tki-jin-a02-shows-promising-anti-tumor-activity-in-resistant-nsclc-patients 2025-06-02T04:53:33+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-activates-first-australian-site-for-phase-ii-colorectal-cancer-vaccine-trial 2025-06-02T04:52:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imugene-activates-first-australian-site-for-phase-ii-colorectal-cancer-vaccine-trial 2025-06-02T04:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-unveil-new-strategies-to-harness-tumor-microenvironment-for-enhanced-cancer-immunotherapy 2025-06-02T03:56:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-unveil-new-strategies-to-harness-tumor-microenvironment-for-enhanced-cancer-immunotherapy 2025-06-02T03:56:20+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-secures-fda-approval-for-leqvio-first-twice-yearly-cholesterol-drug 2025-06-02T03:39:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-secures-fda-approval-for-leqvio-first-twice-yearly-cholesterol-drug 2025-06-02T03:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/mammaprint-70-gene-assay-shows-strong-predictive-value-for-chemotherapy-benefit-in-hr-her2-breast-cancer 2025-06-02T02:51:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mammaprint-70-gene-assay-shows-strong-predictive-value-for-chemotherapy-benefit-in-hr-her2-breast-cancer 2025-06-02T02:51:24+00:00 hourly 0.9 https://trial.medpath.com/news/era-2025-to-feature-pivotal-nephrology-trials-including-confidence-achieve-and-visionary-studies 2025-06-02T02:51:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/era-2025-to-feature-pivotal-nephrology-trials-including-confidence-achieve-and-visionary-studies 2025-06-02T02:51:23+00:00 hourly 0.9 https://trial.medpath.com/news/novoxel-and-gpophtho-partner-to-expand-access-to-fda-cleared-tixel-device-for-dry-eye-treatment-across-us 2025-06-02T01:50:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novoxel-and-gpophtho-partner-to-expand-access-to-fda-cleared-tixel-device-for-dry-eye-treatment-across-us 2025-06-02T01:50:58+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-achieves-key-development-milestone-in-eli-lilly-collaboration-for-diabetes-and-metabolic-disease-treatments 2025-06-02T00:52:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nxera-pharma-achieves-key-development-milestone-in-eli-lilly-collaboration-for-diabetes-and-metabolic-disease-treatments 2025-06-02T00:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-grants-conditional-approval-for-car-t-therapy-aucatzyl-to-treat-relapsed-b-cell-all 2025-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-grants-conditional-approval-for-car-t-therapy-aucatzyl-to-treat-relapsed-b-cell-all 2025-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mirvie-s-rna-blood-test-predicts-preeclampsia-risk-months-before-symptoms-in-major-study 2025-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirvie-s-rna-blood-test-predicts-preeclampsia-risk-months-before-symptoms-in-major-study 2025-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-confirms-low-severity-safety-profile-for-lisocabtagene-maraleucel-across-blood-cancer-settings 2025-06-01T20:51:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-confirms-low-severity-safety-profile-for-lisocabtagene-maraleucel-across-blood-cancer-settings 2025-06-01T20:51:31+00:00 hourly 0.9 https://trial.medpath.com/news/sintilimab-chidamide-combination-shows-promising-results-in-early-stage-natural-killer-t-cell-lymphoma 2025-06-01T18:50:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sintilimab-chidamide-combination-shows-promising-results-in-early-stage-natural-killer-t-cell-lymphoma 2025-06-01T18:50:24+00:00 hourly 0.9 https://trial.medpath.com/news/anti-inflammatory-diet-reduces-death-risk-by-87-in-stage-iii-colon-cancer-patients 2025-06-01T17:52:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anti-inflammatory-diet-reduces-death-risk-by-87-in-stage-iii-colon-cancer-patients 2025-06-01T17:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-shows-yescarta-car-t-therapy-safe-and-effective-in-outpatient-setting 2025-06-01T17:51:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-shows-yescarta-car-t-therapy-safe-and-effective-in-outpatient-setting 2025-06-01T17:51:33+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-s-dual-target-car-t-therapy-achieves-62-response-rate-in-recurrent-glioblastoma 2025-06-01T16:54:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-s-dual-target-car-t-therapy-achieves-62-response-rate-in-recurrent-glioblastoma 2025-06-01T16:54:28+00:00 hourly 0.9 https://trial.medpath.com/news/dual-target-car-t-cell-therapy-achieves-tumor-shrinkage-in-62-of-recurrent-glioblastoma-patients 2025-06-01T16:53:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-target-car-t-cell-therapy-achieves-tumor-shrinkage-in-62-of-recurrent-glioblastoma-patients 2025-06-01T16:53:30+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-clinical-trial-demonstrates-exercise-significantly-improves-colon-cancer-survival 2025-06-01T16:53:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-clinical-trial-demonstrates-exercise-significantly-improves-colon-cancer-survival 2025-06-01T16:53:21+00:00 hourly 0.9 https://trial.medpath.com/news/casdatifan-plus-cabozantinib-combination-shows-46-response-rate-in-kidney-cancer-trial 2025-06-01T16:52:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/casdatifan-plus-cabozantinib-combination-shows-46-response-rate-in-kidney-cancer-trial 2025-06-01T16:52:28+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-pasritamig-shows-promising-anti-tumor-activity-in-first-in-human-prostate-cancer-trial 2025-06-01T16:52:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-pasritamig-shows-promising-anti-tumor-activity-in-first-in-human-prostate-cancer-trial 2025-06-01T16:52:26+00:00 hourly 0.9 https://trial.medpath.com/news/structured-exercise-program-reduces-colon-cancer-recurrence-by-28-in-landmark-international-trial 2025-06-01T16:50:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structured-exercise-program-reduces-colon-cancer-recurrence-by-28-in-landmark-international-trial 2025-06-01T16:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/regorafenib-shows-promise-as-first-line-treatment-for-multi-metastatic-ewing-sarcoma-in-phase-ib-trial 2025-06-01T16:50:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regorafenib-shows-promise-as-first-line-treatment-for-multi-metastatic-ewing-sarcoma-in-phase-ib-trial 2025-06-01T16:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-plus-chemotherapy-reduces-recurrence-risk-by-50-in-stage-iii-dmmr-colon-cancer 2025-06-01T16:49:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atezolizumab-plus-chemotherapy-reduces-recurrence-risk-by-50-in-stage-iii-dmmr-colon-cancer 2025-06-01T16:49:30+00:00 hourly 0.9 https://trial.medpath.com/news/replimune-s-rp1-combination-shows-enhanced-response-rates-with-deep-tumor-injections-in-anti-pd-1-failed-melanoma 2025-06-01T16:49:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/replimune-s-rp1-combination-shows-enhanced-response-rates-with-deep-tumor-injections-in-anti-pd-1-failed-melanoma 2025-06-01T16:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/narirutin-accelerates-diabetic-wound-healing-through-ampk-mfn2-mediated-metabolic-reprogramming 2025-06-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/narirutin-accelerates-diabetic-wound-healing-through-ampk-mfn2-mediated-metabolic-reprogramming 2025-06-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-requests-additional-clinical-data-from-fresenius-for-calcium-chloride-infusion-approval-in-india 2025-06-01T12:43:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-requests-additional-clinical-data-from-fresenius-for-calcium-chloride-infusion-approval-in-india 2025-06-01T12:43:45+00:00 hourly 0.9 https://trial.medpath.com/news/dea-blocks-cannabis-research-for-seven-years-despite-fda-approved-clinical-trials-for-huntington-s-disease-and-multiple-sclerosis 2025-06-01T12:43:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-blocks-cannabis-research-for-seven-years-despite-fda-approved-clinical-trials-for-huntington-s-disease-and-multiple-sclerosis 2025-06-01T12:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/inxmed-reports-breakthrough-results-for-ifebemtinib-garsorasib-combination-in-kras-g12c-mutant-cancers-at-asco-2025 2025-06-01T08:57:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inxmed-reports-breakthrough-results-for-ifebemtinib-garsorasib-combination-in-kras-g12c-mutant-cancers-at-asco-2025 2025-06-01T08:57:43+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-emerges-as-key-factor-in-cancer-immunotherapy-response-and-resistance 2025-06-01T03:53:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiome-emerges-as-key-factor-in-cancer-immunotherapy-response-and-resistance 2025-06-01T03:53:03+00:00 hourly 0.9 https://trial.medpath.com/news/lbl-024-bispecific-antibody-shows-75-response-rate-in-advanced-neuroendocrine-carcinoma-trial 2025-06-01T00:46:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lbl-024-bispecific-antibody-shows-75-response-rate-in-advanced-neuroendocrine-carcinoma-trial 2025-06-01T00:46:02+00:00 hourly 0.9 https://trial.medpath.com/news/neocoast-2-trial-shows-promise-for-novel-pre-surgical-combinations-in-resectable-nsclc 2025-06-01T00:45:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neocoast-2-trial-shows-promise-for-novel-pre-surgical-combinations-in-resectable-nsclc 2025-06-01T00:45:10+00:00 hourly 0.9 https://trial.medpath.com/news/avistone-s-dual-target-therapy-shows-50-response-rate-in-egfr-resistant-lung-cancer-at-asco-2025 2025-06-01T00:44:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avistone-s-dual-target-therapy-shows-50-response-rate-in-egfr-resistant-lung-cancer-at-asco-2025 2025-06-01T00:44:32+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-partners-with-healthex-to-transform-patient-data-consent-using-ai-driven-platform 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-partners-with-healthex-to-transform-patient-data-consent-using-ai-driven-platform 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-advances-two-phase-iii-trials-testing-baxdrostat-combination-therapy-for-cardiovascular-and-kidney-disease 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-advances-two-phase-iii-trials-testing-baxdrostat-combination-therapy-for-cardiovascular-and-kidney-disease 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-domestically-developed-9-valent-hpv-vaccine-becomes-second-country-with-independent-high-valency-hpv-production 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-domestically-developed-9-valent-hpv-vaccine-becomes-second-country-with-independent-high-valency-hpv-production 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-initiates-phase-ii-trial-of-azd7798-for-crohn-s-disease-mucosal-repair 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-initiates-phase-ii-trial-of-azd7798-for-crohn-s-disease-mucosal-repair 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-advances-azd0022-novel-oral-krasg12d-inhibitor-in-first-in-human-phase-i-iia-trial 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-advances-azd0022-novel-oral-krasg12d-inhibitor-in-first-in-human-phase-i-iia-trial 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/harbinger-health-s-blood-based-multi-cancer-test-shows-promise-in-high-risk-obesity-population-at-asco-2025 2025-05-31T22:50:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbinger-health-s-blood-based-multi-cancer-test-shows-promise-in-high-risk-obesity-population-at-asco-2025 2025-05-31T22:50:54+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-life-sciences-partners-with-ontada-to-enhance-real-world-oncology-data-analytics-for-drug-development 2025-05-31T20:44:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-life-sciences-partners-with-ontada-to-enhance-real-world-oncology-data-analytics-for-drug-development 2025-05-31T20:44:17+00:00 hourly 0.9 https://trial.medpath.com/news/napoli-3-post-hoc-analysis-identifies-characteristics-associated-with-long-term-survival-in-metastatic-pancreatic-cancer 2025-05-31T20:44:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/napoli-3-post-hoc-analysis-identifies-characteristics-associated-with-long-term-survival-in-metastatic-pancreatic-cancer 2025-05-31T20:44:06+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-study-reveals-significant-racial-disparities-in-early-onset-colorectal-cancer-diagnosis 2025-05-31T19:51:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-study-reveals-significant-racial-disparities-in-early-onset-colorectal-cancer-diagnosis 2025-05-31T19:51:16+00:00 hourly 0.9 https://trial.medpath.com/news/facet-life-sciences-partners-with-nucleus-to-advance-radiopharmaceutical-development-through-regulatory-expertise 2025-05-31T16:57:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/facet-life-sciences-partners-with-nucleus-to-advance-radiopharmaceutical-development-through-regulatory-expertise 2025-05-31T16:57:43+00:00 hourly 0.9 https://trial.medpath.com/news/dual-immunotherapy-combination-significantly-extends-survival-in-advanced-cutaneous-squamous-cell-carcinoma 2025-05-31T16:55:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-immunotherapy-combination-significantly-extends-survival-in-advanced-cutaneous-squamous-cell-carcinoma 2025-05-31T16:55:25+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-based-mrd-testing-shows-superior-prognostic-value-in-dlbcl-first-line-treatment 2025-05-31T16:55:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctdna-based-mrd-testing-shows-superior-prognostic-value-in-dlbcl-first-line-treatment 2025-05-31T16:55:09+00:00 hourly 0.9 https://trial.medpath.com/news/artera-s-ai-algorithm-identifies-which-prostate-cancer-patients-benefit-from-intensive-therapy-earning-best-of-asco-recognition 2025-05-31T14:54:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artera-s-ai-algorithm-identifies-which-prostate-cancer-patients-benefit-from-intensive-therapy-earning-best-of-asco-recognition 2025-05-31T14:54:18+00:00 hourly 0.9 https://trial.medpath.com/news/14-gene-molecular-assay-guides-adjuvant-chemotherapy-in-early-stage-nsclc-reduces-recurrence-risk-by-78 2025-05-31T14:53:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/14-gene-molecular-assay-guides-adjuvant-chemotherapy-in-early-stage-nsclc-reduces-recurrence-risk-by-78 2025-05-31T14:53:55+00:00 hourly 0.9 https://trial.medpath.com/news/transcripta-bio-partners-with-microsoft-research-to-accelerate-ai-driven-disease-gene-discovery 2025-05-31T11:51:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcripta-bio-partners-with-microsoft-research-to-accelerate-ai-driven-disease-gene-discovery 2025-05-31T11:51:06+00:00 hourly 0.9 https://trial.medpath.com/news/subtle-medical-expands-ai-powered-mri-enhancement-technology-across-latin-america-with-anvisa-approval-in-brazil 2025-05-31T09:52:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subtle-medical-expands-ai-powered-mri-enhancement-technology-across-latin-america-with-anvisa-approval-in-brazil 2025-05-31T09:52:56+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-and-capricor-secure-fda-orphan-drug-designations-for-rare-disease-treatments 2025-05-31T08:55:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beam-therapeutics-and-capricor-secure-fda-orphan-drug-designations-for-rare-disease-treatments 2025-05-31T08:55:04+00:00 hourly 0.9 https://trial.medpath.com/news/dual-targeted-car-t-therapy-kite-363-shows-87-response-rate-in-relapsed-b-cell-lymphoma 2025-05-31T08:54:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-targeted-car-t-therapy-kite-363-shows-87-response-rate-in-relapsed-b-cell-lymphoma 2025-05-31T08:54:26+00:00 hourly 0.9 https://trial.medpath.com/news/epcoritamab-demonstrates-durable-3-year-remissions-in-relapsed-refractory-large-b-cell-lymphoma 2025-05-31T07:51:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epcoritamab-demonstrates-durable-3-year-remissions-in-relapsed-refractory-large-b-cell-lymphoma 2025-05-31T07:51:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-to-streamline-color-additive-replacement-in-drug-products 2025-05-31T06:51:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-to-streamline-color-additive-replacement-in-drug-products 2025-05-31T06:51:58+00:00 hourly 0.9 https://trial.medpath.com/news/circode-biomed-s-hm2002-becomes-world-s-first-circular-rna-drug-to-receive-fda-ind-clearance-for-ischemic-heart-disease 2025-05-31T04:52:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circode-biomed-s-hm2002-becomes-world-s-first-circular-rna-drug-to-receive-fda-ind-clearance-for-ischemic-heart-disease 2025-05-31T04:52:55+00:00 hourly 0.9 https://trial.medpath.com/news/patient-caregiver-preferences-study-reveals-key-treatment-decision-factors-in-alk-nsclc 2025-05-31T03:51:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-caregiver-preferences-study-reveals-key-treatment-decision-factors-in-alk-nsclc 2025-05-31T03:51:15+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-halts-major-hiv-vaccine-research-programs-despite-scientific-progress 2025-05-31T02:53:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-halts-major-hiv-vaccine-research-programs-despite-scientific-progress 2025-05-31T02:53:54+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-based-immune-risk-score-outperforms-traditional-methods-in-predicting-colorectal-cancer-outcomes 2025-05-31T02:52:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-based-immune-risk-score-outperforms-traditional-methods-in-predicting-colorectal-cancer-outcomes 2025-05-31T02:52:58+00:00 hourly 0.9 https://trial.medpath.com/news/stage-4-lung-cancer-patient-achieves-complete-response-with-pembrolizumab-immunotherapy 2025-05-31T00:57:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stage-4-lung-cancer-patient-achieves-complete-response-with-pembrolizumab-immunotherapy 2025-05-31T00:57:29+00:00 hourly 0.9 https://trial.medpath.com/news/frontotemporal-dementia-therapeutics-enter-new-era-as-gene-and-antibody-therapies-advance-toward-market 2025-05-31T00:56:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frontotemporal-dementia-therapeutics-enter-new-era-as-gene-and-antibody-therapies-advance-toward-market 2025-05-31T00:56:28+00:00 hourly 0.9 https://trial.medpath.com/news/her3-dxd-demonstrates-promising-intracranial-activity-in-phase-ii-tuxedo-3-trial-for-brain-metastases 2025-05-31T00:55:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/her3-dxd-demonstrates-promising-intracranial-activity-in-phase-ii-tuxedo-3-trial-for-brain-metastases 2025-05-31T00:55:04+00:00 hourly 0.9 https://trial.medpath.com/news/sleipnir-multi-arm-platform-receives-ps1-million-to-accelerate-parkinson-s-drug-development-in-norway 2025-05-31T00:54:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sleipnir-multi-arm-platform-receives-ps1-million-to-accelerate-parkinson-s-drug-development-in-norway 2025-05-31T00:54:19+00:00 hourly 0.9 https://trial.medpath.com/news/meitheal-pharmaceuticals-launches-generic-abraxane-in-us-market-to-address-cancer-treatment-access 2025-05-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meitheal-pharmaceuticals-launches-generic-abraxane-in-us-market-to-address-cancer-treatment-access 2025-05-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immuron-advances-multi-drug-pipeline-with-fda-submissions-and-clinical-milestones-on-track-for-2025 2025-05-30T23:53:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuron-advances-multi-drug-pipeline-with-fda-submissions-and-clinical-milestones-on-track-for-2025 2025-05-30T23:53:59+00:00 hourly 0.9 https://trial.medpath.com/news/riboscience-s-first-in-class-enpp1-inhibitor-rbs2418-shows-promising-safety-and-efficacy-in-phase-1a-cancer-trial 2025-05-30T23:51:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/riboscience-s-first-in-class-enpp1-inhibitor-rbs2418-shows-promising-safety-and-efficacy-in-phase-1a-cancer-trial 2025-05-30T23:51:54+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-romiplostim-shows-breakthrough-results-for-chemotherapy-induced-thrombocytopenia-with-nccn-endorsement 2025-05-30T23:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-romiplostim-shows-breakthrough-results-for-chemotherapy-induced-thrombocytopenia-with-nccn-endorsement 2025-05-30T23:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/femasys-raises-4-5-million-to-advance-women-s-health-technologies-including-fembloc-birth-control 2025-05-30T22:54:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/femasys-raises-4-5-million-to-advance-women-s-health-technologies-including-fembloc-birth-control 2025-05-30T22:54:36+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-safe-rechallenge-with-trastuzumab-deruxtecan-after-grade-1-interstitial-lung-disease 2025-05-30T22:50:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-safe-rechallenge-with-trastuzumab-deruxtecan-after-grade-1-interstitial-lung-disease 2025-05-30T22:50:02+00:00 hourly 0.9 https://trial.medpath.com/news/mrpl-secures-us-patent-for-pharmaceutical-intermediate-production-technology 2025-05-30T20:52:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrpl-secures-us-patent-for-pharmaceutical-intermediate-production-technology 2025-05-30T20:52:40+00:00 hourly 0.9 https://trial.medpath.com/news/investor-lawsuit-challenges-novartis-1-7-billion-acquisition-of-regulus-therapeutics-over-kidney-disease-drug 2025-05-30T20:52:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/investor-lawsuit-challenges-novartis-1-7-billion-acquisition-of-regulus-therapeutics-over-kidney-disease-drug 2025-05-30T20:52:03+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-novel-long-acting-g-csf-drug-mailisheng-receives-nmpa-approval-for-chemotherapy-induced-neutropenia 2025-05-30T20:51:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-s-novel-long-acting-g-csf-drug-mailisheng-receives-nmpa-approval-for-chemotherapy-induced-neutropenia 2025-05-30T20:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/patritumab-deruxtecan-demonstrates-promising-efficacy-in-first-prospective-trial-for-leptomeningeal-metastases 2025-05-30T20:51:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patritumab-deruxtecan-demonstrates-promising-efficacy-in-first-prospective-trial-for-leptomeningeal-metastases 2025-05-30T20:51:36+00:00 hourly 0.9 https://trial.medpath.com/news/teddy-laboratory-and-labconnect-form-strategic-partnership-to-enhance-global-clinical-trial-services 2025-05-30T20:50:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teddy-laboratory-and-labconnect-form-strategic-partnership-to-enhance-global-clinical-trial-services 2025-05-30T20:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/her3-targeted-adc-db-1310-shows-promising-results-in-advanced-solid-tumors-particularly-egfr-mutant-nsclc 2025-05-30T19:53:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/her3-targeted-adc-db-1310-shows-promising-results-in-advanced-solid-tumors-particularly-egfr-mutant-nsclc 2025-05-30T19:53:28+00:00 hourly 0.9 https://trial.medpath.com/news/carlyle-and-sk-capital-complete-3-5-per-share-acquisition-of-gene-therapy-pioneer-bluebird-bio 2025-05-30T19:52:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carlyle-and-sk-capital-complete-3-5-per-share-acquisition-of-gene-therapy-pioneer-bluebird-bio 2025-05-30T19:52:55+00:00 hourly 0.9 https://trial.medpath.com/news/vizgen-and-hamamatsu-form-strategic-partnership-to-advance-spatial-biology-workflows-for-cancer-research 2025-05-30T18:50:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vizgen-and-hamamatsu-form-strategic-partnership-to-advance-spatial-biology-workflows-for-cancer-research 2025-05-30T18:50:27+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-s-adc-precemtabart-tocentecan-shows-promising-safety-and-efficacy-in-metastatic-colorectal-cancer-trial 2025-05-30T17:50:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-s-adc-precemtabart-tocentecan-shows-promising-safety-and-efficacy-in-metastatic-colorectal-cancer-trial 2025-05-30T17:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/mapmygenome-acquires-microbiome-insights-to-expand-global-genomics-and-microbiome-research-capabilities 2025-05-30T16:58:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mapmygenome-acquires-microbiome-insights-to-expand-global-genomics-and-microbiome-research-capabilities 2025-05-30T16:58:11+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-for-severe-autoimmune-neurological-diseases-in-pioneering-european-studies 2025-05-30T16:56:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-promise-for-severe-autoimmune-neurological-diseases-in-pioneering-european-studies 2025-05-30T16:56:33+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-cell-therapy-allo-316-shows-33-response-rate-in-advanced-renal-cell-carcinoma 2025-05-30T16:56:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-t-cell-therapy-allo-316-shows-33-response-rate-in-advanced-renal-cell-carcinoma 2025-05-30T16:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/cofactor-genomics-ai-powered-rna-platform-shows-300-400-improvement-in-predicting-cancer-immunotherapy-response 2025-05-30T16:55:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cofactor-genomics-ai-powered-rna-platform-shows-300-400-improvement-in-predicting-cancer-immunotherapy-response 2025-05-30T16:55:55+00:00 hourly 0.9 https://trial.medpath.com/news/universal-car-t-cell-therapy-achieves-91-response-rate-in-aggressive-t-cell-cancers 2025-05-30T16:55:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/universal-car-t-cell-therapy-achieves-91-response-rate-in-aggressive-t-cell-cancers 2025-05-30T16:55:51+00:00 hourly 0.9 https://trial.medpath.com/news/coherus-biosciences-rebrands-as-coherus-oncology-advances-immuno-oncology-pipeline-with-novel-combination-therapies 2025-05-30T16:55:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coherus-biosciences-rebrands-as-coherus-oncology-advances-immuno-oncology-pipeline-with-novel-combination-therapies 2025-05-30T16:55:13+00:00 hourly 0.9 https://trial.medpath.com/news/bambusa-therapeutics-doses-first-patient-with-bbt002-bispecific-antibody-and-receives-fda-clearance-for-bbt001 2025-05-30T16:55:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bambusa-therapeutics-doses-first-patient-with-bbt002-bispecific-antibody-and-receives-fda-clearance-for-bbt001 2025-05-30T16:55:03+00:00 hourly 0.9 https://trial.medpath.com/news/polyactiva-secures-40m-series-c-to-advance-revolutionary-glaucoma-implant-technology 2025-05-30T16:54:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polyactiva-secures-40m-series-c-to-advance-revolutionary-glaucoma-implant-technology 2025-05-30T16:54:51+00:00 hourly 0.9 https://trial.medpath.com/news/pancreatic-cancer-pipeline-expands-with-80-companies-advancing-novel-therapies 2025-05-30T16:54:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pancreatic-cancer-pipeline-expands-with-80-companies-advancing-novel-therapies 2025-05-30T16:54:39+00:00 hourly 0.9 https://trial.medpath.com/news/myeloid-therapeutics-reports-first-in-human-data-for-in-vivo-mrna-car-therapies-at-asco-2025 2025-05-30T16:52:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myeloid-therapeutics-reports-first-in-human-data-for-in-vivo-mrna-car-therapies-at-asco-2025 2025-05-30T16:52:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-de-novo-clearance-for-reflow-medical-s-spur-retrievable-stent-system-for-below-the-knee-arterial-disease 2025-05-30T16:52:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-de-novo-clearance-for-reflow-medical-s-spur-retrievable-stent-system-for-below-the-knee-arterial-disease 2025-05-30T16:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-s-eo4010-shows-promising-survival-data-in-difficult-to-treat-colorectal-cancer-at-asco-2025 2025-05-30T12:52:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterome-s-eo4010-shows-promising-survival-data-in-difficult-to-treat-colorectal-cancer-at-asco-2025 2025-05-30T12:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-defense-department-partners-with-cepi-to-advance-nipah-virus-monoclonal-antibody-treatment 2025-05-30T12:52:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-defense-department-partners-with-cepi-to-advance-nipah-virus-monoclonal-antibody-treatment 2025-05-30T12:52:09+00:00 hourly 0.9 https://trial.medpath.com/news/biolinerx-reports-promising-pancreatic-cancer-trial-results-with-64-response-rate-for-motixafortide-combination 2025-05-30T12:52:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biolinerx-reports-promising-pancreatic-cancer-trial-results-with-64-response-rate-for-motixafortide-combination 2025-05-30T12:52:05+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-announces-potential-5-billion-drug-licensing-deals-following-q1-revenue-decline 2025-05-30T12:51:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-pharmaceutical-announces-potential-5-billion-drug-licensing-deals-following-q1-revenue-decline 2025-05-30T12:51:50+00:00 hourly 0.9 https://trial.medpath.com/news/gc-biopharma-s-hunterase-shows-significant-efficacy-in-phase-3-trial-for-hunter-syndrome 2025-05-30T12:50:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-biopharma-s-hunterase-shows-significant-efficacy-in-phase-3-trial-for-hunter-syndrome 2025-05-30T12:50:58+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-secures-korean-approval-for-denosumab-biosimilar-xbryk-completing-global-regulatory-trifecta 2025-05-30T12:50:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-secures-korean-approval-for-denosumab-biosimilar-xbryk-completing-global-regulatory-trifecta 2025-05-30T12:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/yuhan-corporation-receives-15-million-milestone-from-janssen-following-japan-launch-of-lazertinib-amivantamab-combination-for-egfr-mutated-nsclc 2025-05-30T12:50:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yuhan-corporation-receives-15-million-milestone-from-janssen-following-japan-launch-of-lazertinib-amivantamab-combination-for-egfr-mutated-nsclc 2025-05-30T12:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-zanidatamab-as-first-dual-her2-targeted-bispecific-antibody-for-biliary-tract-cancer 2025-05-30T12:50:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-zanidatamab-as-first-dual-her2-targeted-bispecific-antibody-for-biliary-tract-cancer 2025-05-30T12:50:06+00:00 hourly 0.9 https://trial.medpath.com/news/marksans-pharma-subsidiary-receives-uk-marketing-authorization-for-metformin-oral-solution 2025-05-30T12:49:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marksans-pharma-subsidiary-receives-uk-marketing-authorization-for-metformin-oral-solution 2025-05-30T12:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-renal-cell-carcinoma-pipeline-shows-strong-growth-with-60-therapies-in-development 2025-05-30T10:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-renal-cell-carcinoma-pipeline-shows-strong-growth-with-60-therapies-in-development 2025-05-30T10:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/outcomes4me-raises-21m-to-expand-ai-driven-cancer-care-platform-globally 2025-05-30T09:53:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outcomes4me-raises-21m-to-expand-ai-driven-cancer-care-platform-globally 2025-05-30T09:53:58+00:00 hourly 0.9 https://trial.medpath.com/news/cardiosense-launches-seismic-hf-ii-study-to-validate-ai-algorithm-for-heart-failure-management 2025-05-30T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiosense-launches-seismic-hf-ii-study-to-validate-ai-algorithm-for-heart-failure-management 2025-05-30T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/itepekimab-shows-mixed-results-in-phase-3-copd-trials-meeting-primary-endpoint-in-one-of-two-studies 2025-05-30T08:44:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itepekimab-shows-mixed-results-in-phase-3-copd-trials-meeting-primary-endpoint-in-one-of-two-studies 2025-05-30T08:44:02+00:00 hourly 0.9 https://trial.medpath.com/news/qv-bioelectronics-secures-ps1-26-million-to-advance-grace-brain-tumor-device-toward-clinical-trials 2025-05-30T08:44:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qv-bioelectronics-secures-ps1-26-million-to-advance-grace-brain-tumor-device-toward-clinical-trials 2025-05-30T08:44:01+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-launches-promoterai-tool-to-detect-disease-causing-mutations-in-previously-overlooked-genomic-regions 2025-05-30T08:43:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-launches-promoterai-tool-to-detect-disease-causing-mutations-in-previously-overlooked-genomic-regions 2025-05-30T08:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/iksuda-therapeutics-initiates-first-in-human-trial-of-cd19-targeted-adc-iks03-for-advanced-b-cell-non-hodgkin-lymphoma 2025-05-30T06:55:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iksuda-therapeutics-initiates-first-in-human-trial-of-cd19-targeted-adc-iks03-for-advanced-b-cell-non-hodgkin-lymphoma 2025-05-30T06:55:34+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-advances-two-experimental-compounds-through-early-stage-clinical-testing 2025-05-30T06:53:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-advances-two-experimental-compounds-through-early-stage-clinical-testing 2025-05-30T06:53:11+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-secures-1-4-billion-license-deal-for-novel-cldn18-2-targeting-adc-xnw27011 2025-05-30T05:02:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-secures-1-4-billion-license-deal-for-novel-cldn18-2-targeting-adc-xnw27011 2025-05-30T05:02:03+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-clinical-trial-identifies-gene-mutations-as-key-to-treating-aggressive-prostate-cancer 2025-05-30T05:00:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-clinical-trial-identifies-gene-mutations-as-key-to-treating-aggressive-prostate-cancer 2025-05-30T05:00:20+00:00 hourly 0.9 https://trial.medpath.com/news/saudi-arabia-launches-national-biotech-initiative-at-bio-2025-with-strategic-partnerships 2025-05-30T04:59:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saudi-arabia-launches-national-biotech-initiative-at-bio-2025-with-strategic-partnerships 2025-05-30T04:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/concurrent-hypertension-and-type-2-diabetes-double-mortality-risk-as-prevalence-surges-in-us-adults 2025-05-30T02:46:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concurrent-hypertension-and-type-2-diabetes-double-mortality-risk-as-prevalence-surges-in-us-adults 2025-05-30T02:46:56+00:00 hourly 0.9 https://trial.medpath.com/news/seer-launches-next-generation-proteomics-platform-enabling-unprecedented-20000-sample-cancer-study 2025-05-30T02:46:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seer-launches-next-generation-proteomics-platform-enabling-unprecedented-20000-sample-cancer-study 2025-05-30T02:46:44+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-supportive-care-emerges-as-critical-component-in-sma-management-beyond-disease-modifying-therapies 2025-05-30T02:46:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-supportive-care-emerges-as-critical-component-in-sma-management-beyond-disease-modifying-therapies 2025-05-30T02:46:32+00:00 hourly 0.9 https://trial.medpath.com/news/made-scientific-expands-princeton-facility-with-12000-sq-ft-gmp-manufacturing-space-for-commercial-cell-therapy-production 2025-05-30T02:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/made-scientific-expands-princeton-facility-with-12000-sq-ft-gmp-manufacturing-space-for-commercial-cell-therapy-production 2025-05-30T02:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-regulatory-framework-provides-multiple-pathways-for-cancer-drug-access-beyond-traditional-approval 2025-05-30T01:58:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-regulatory-framework-provides-multiple-pathways-for-cancer-drug-access-beyond-traditional-approval 2025-05-30T01:58:25+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-secures-lenvima-patent-protection-through-2036-in-us-court-victory 2025-05-30T01:47:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-secures-lenvima-patent-protection-through-2036-in-us-court-victory 2025-05-30T01:47:32+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-approval-for-hs-10542-capsules-issued-by-nmpa 2025-05-30T00:57:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-approval-for-hs-10542-capsules-issued-by-nmpa 2025-05-30T00:57:53+00:00 hourly 0.9 https://trial.medpath.com/news/delaware-judge-limits-liquidia-s-patent-defense-strategies-in-utc-lung-disease-drug-dispute 2025-05-30T00:47:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delaware-judge-limits-liquidia-s-patent-defense-strategies-in-utc-lung-disease-drug-dispute 2025-05-30T00:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/cellares-and-mitsui-fudosan-launch-japan-s-first-automated-car-t-manufacturing-facility 2025-05-30T00:47:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellares-and-mitsui-fudosan-launch-japan-s-first-automated-car-t-manufacturing-facility 2025-05-30T00:47:25+00:00 hourly 0.9 https://trial.medpath.com/news/parker-institute-showcases-breakthroughs-in-immunotherapy-at-asco-2025-as-ceo-dr 2025-05-30T00:47:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parker-institute-showcases-breakthroughs-in-immunotherapy-at-asco-2025-as-ceo-dr 2025-05-30T00:47:21+00:00 hourly 0.9 https://trial.medpath.com/news/acceptance-of-a-new-drug-application-for-naldemedine-a-treatment-for-opioid-induced 2025-05-30T00:46:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acceptance-of-a-new-drug-application-for-naldemedine-a-treatment-for-opioid-induced 2025-05-30T00:46:44+00:00 hourly 0.9 https://trial.medpath.com/news/us-fda-s-prasad-we-will-always-embrace-surrogate-endpoints-citeline-news-insights 2025-05-30T00:45:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-fda-s-prasad-we-will-always-embrace-surrogate-endpoints-citeline-news-insights 2025-05-30T00:45:32+00:00 hourly 0.9 https://trial.medpath.com/news/danaher-partners-with-astrazeneca-to-develop-ai-powered-precision-medicine-diagnostics 2025-05-30T00:17:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/danaher-partners-with-astrazeneca-to-develop-ai-powered-precision-medicine-diagnostics 2025-05-30T00:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/ai-test-identifies-prostate-cancer-patients-who-benefit-most-from-life-saving-drug-abiraterone 2025-05-30T00:17:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-test-identifies-prostate-cancer-patients-who-benefit-most-from-life-saving-drug-abiraterone 2025-05-30T00:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-phase-2-trial-reveals-circulating-tumor-dna-as-key-biomarker-for-personalized-prostate-cancer-treatment 2025-05-30T00:16:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-phase-2-trial-reveals-circulating-tumor-dna-as-key-biomarker-for-personalized-prostate-cancer-treatment 2025-05-30T00:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/invion-s-inv043-photodynamic-therapy-shows-promise-in-phase-i-ii-non-melanoma-skin-cancer-trial 2025-05-30T00:16:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invion-s-inv043-photodynamic-therapy-shows-promise-in-phase-i-ii-non-melanoma-skin-cancer-trial 2025-05-30T00:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-treatment-strategies-transform-pulmonary-arterial-hypertension-management-through-multi-pathway-approach 2025-05-30T00:15:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-treatment-strategies-transform-pulmonary-arterial-hypertension-management-through-multi-pathway-approach 2025-05-30T00:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/cirm-awards-4-7-million-to-advance-aav-gene-therapy-for-blue-cone-monochromacy 2025-05-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cirm-awards-4-7-million-to-advance-aav-gene-therapy-for-blue-cone-monochromacy 2025-05-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/remegen-s-telitacicept-receives-approval-in-china-for-generalized-myasthenia-gravis-treatment 2025-05-29T21:49:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remegen-s-telitacicept-receives-approval-in-china-for-generalized-myasthenia-gravis-treatment 2025-05-29T21:49:17+00:00 hourly 0.9 https://trial.medpath.com/news/modular-medical-strengthens-board-with-generic-insulin-expert-jeff-goldberg 2025-05-29T21:46:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modular-medical-strengthens-board-with-generic-insulin-expert-jeff-goldberg 2025-05-29T21:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/bioquebec-and-life-sciences-british-columbia-form-strategic-alliance-to-strengthen-canada-s-life-sciences-ecosystem 2025-05-29T20:48:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioquebec-and-life-sciences-british-columbia-form-strategic-alliance-to-strengthen-canada-s-life-sciences-ecosystem 2025-05-29T20:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/investigational-monoclonal-antibody-tb006-shows-promise-in-reversing-alzheimer-s-disease-through-galectin-3-targeting 2025-05-29T20:47:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/investigational-monoclonal-antibody-tb006-shows-promise-in-reversing-alzheimer-s-disease-through-galectin-3-targeting 2025-05-29T20:47:32+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bag3-expressing-gene-therapy-shows-promise-for-ibm-bioworld 2025-05-29T20:47:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bag3-expressing-gene-therapy-shows-promise-for-ibm-bioworld 2025-05-29T20:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/kenya-slashes-breast-cancer-treatment-costs-by-67-through-roche-partnership 2025-05-29T20:47:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kenya-slashes-breast-cancer-treatment-costs-by-67-through-roche-partnership 2025-05-29T20:47:15+00:00 hourly 0.9 https://trial.medpath.com/news/neuronata-r-stem-cell-therapy-shows-promise-in-als-subgroup-targets-fda-accelerated-approval 2025-05-29T20:47:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuronata-r-stem-cell-therapy-shows-promise-in-als-subgroup-targets-fda-accelerated-approval 2025-05-29T20:47:11+00:00 hourly 0.9 https://trial.medpath.com/news/acclaro-medical-secures-23-million-series-b-funding-to-advance-revolutionary-2910-nm-fiber-laser-technology-for-aesthetic-medicine 2025-05-29T20:46:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acclaro-medical-secures-23-million-series-b-funding-to-advance-revolutionary-2910-nm-fiber-laser-technology-for-aesthetic-medicine 2025-05-29T20:46:38+00:00 hourly 0.9 https://trial.medpath.com/news/accelus-secures-growth-financing-to-advance-expandable-spinal-implant-technology 2025-05-29T20:15:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accelus-secures-growth-financing-to-advance-expandable-spinal-implant-technology 2025-05-29T20:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/navigator-medicines-initiates-phase-1b-trial-of-nav-240-bispecific-antibody-for-autoimmune-diseases 2025-05-29T20:14:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navigator-medicines-initiates-phase-1b-trial-of-nav-240-bispecific-antibody-for-autoimmune-diseases 2025-05-29T20:14:52+00:00 hourly 0.9 https://trial.medpath.com/news/lyowave-secures-300k-nsf-grant-to-scale-microwave-enhanced-freeze-drying-technology-for-pharmaceutical-manufacturing 2025-05-29T20:14:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lyowave-secures-300k-nsf-grant-to-scale-microwave-enhanced-freeze-drying-technology-for-pharmaceutical-manufacturing 2025-05-29T20:14:48+00:00 hourly 0.9 https://trial.medpath.com/news/cdmos-expand-end-to-end-services-and-facilities-to-meet-growing-pharmaceutical-manufacturing-demands 2025-05-29T20:14:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdmos-expand-end-to-end-services-and-facilities-to-meet-growing-pharmaceutical-manufacturing-demands 2025-05-29T20:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/keros-therapeutics-discontinues-pah-drug-development-following-safety-concerns-in-phase-2-trial 2025-05-29T20:14:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keros-therapeutics-discontinues-pah-drug-development-following-safety-concerns-in-phase-2-trial 2025-05-29T20:14:43+00:00 hourly 0.9 https://trial.medpath.com/news/skytrofa-receives-australian-approval-as-first-once-weekly-growth-hormone-therapy-for-children 2025-05-29T20:13:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skytrofa-receives-australian-approval-as-first-once-weekly-growth-hormone-therapy-for-children 2025-05-29T20:13:25+00:00 hourly 0.9 https://trial.medpath.com/news/rune-labs-and-parkinson-s-foundation-launch-groundbreaking-study-combining-genetic-testing-with-ai-powered-digital-biomarkers 2025-05-29T20:13:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rune-labs-and-parkinson-s-foundation-launch-groundbreaking-study-combining-genetic-testing-with-ai-powered-digital-biomarkers 2025-05-29T20:13:14+00:00 hourly 0.9 https://trial.medpath.com/news/australian-federal-court-streamlines-preliminary-discovery-process-for-pharmaceutical-patent-disputes 2025-05-29T20:13:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-federal-court-streamlines-preliminary-discovery-process-for-pharmaceutical-patent-disputes 2025-05-29T20:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/nih-scientists-report-breakthrough-plant-derived-therapy-reduces-intractable-cancer-pain-by-38 2025-05-29T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-scientists-report-breakthrough-plant-derived-therapy-reduces-intractable-cancer-pain-by-38 2025-05-29T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-delivery-system-successfully-reactivates-latent-hiv-in-resting-t-cells 2025-05-29T18:51:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-delivery-system-successfully-reactivates-latent-hiv-in-resting-t-cells 2025-05-29T18:51:37+00:00 hourly 0.9 https://trial.medpath.com/news/teva-unveils-5-billion-growth-strategy-with-five-potential-blockbuster-drugs-in-late-stage-pipeline 2025-05-29T18:50:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-unveils-5-billion-growth-strategy-with-five-potential-blockbuster-drugs-in-late-stage-pipeline 2025-05-29T18:50:10+00:00 hourly 0.9 https://trial.medpath.com/news/hedera-dx-secures-eur15-million-series-a-to-expand-decentralized-liquid-biopsy-platform-across-europe 2025-05-29T18:47:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hedera-dx-secures-eur15-million-series-a-to-expand-decentralized-liquid-biopsy-platform-across-europe 2025-05-29T18:47:54+00:00 hourly 0.9 https://trial.medpath.com/news/cornell-develops-stealthy-lipid-nanoparticles-to-enhance-mrna-vaccine-delivery-and-reduce-immune-side-effects 2025-05-29T18:46:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cornell-develops-stealthy-lipid-nanoparticles-to-enhance-mrna-vaccine-delivery-and-reduce-immune-side-effects 2025-05-29T18:46:43+00:00 hourly 0.9 https://trial.medpath.com/news/as-the-fda-and-nih-eschew-animal-testing-startup-raises-40-million-for-lab-grown-organs 2025-05-29T17:47:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/as-the-fda-and-nih-eschew-animal-testing-startup-raises-40-million-for-lab-grown-organs 2025-05-29T17:47:18+00:00 hourly 0.9 https://trial.medpath.com/news/medicilon-successfully-passes-fda-inspection-strengthening-global-preclinical-r-d-capabilities 2025-05-29T17:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicilon-successfully-passes-fda-inspection-strengthening-global-preclinical-r-d-capabilities 2025-05-29T17:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/sentinel-biotherapeutics-launches-with-novel-il-2-immunotherapy-platform-for-solid-tumors 2025-05-29T16:50:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sentinel-biotherapeutics-launches-with-novel-il-2-immunotherapy-platform-for-solid-tumors 2025-05-29T16:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/cerus-corporation-reports-positive-phase-3-results-for-intercept-blood-system-at-isbt-congress 2025-05-29T16:50:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerus-corporation-reports-positive-phase-3-results-for-intercept-blood-system-at-isbt-congress 2025-05-29T16:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/ludwig-enterprises-develops-non-invasive-breast-cancer-screening-test-using-buccal-cell-mrna-analysis 2025-05-29T16:49:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ludwig-enterprises-develops-non-invasive-breast-cancer-screening-test-using-buccal-cell-mrna-analysis 2025-05-29T16:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/dx-vx-advances-universal-covid-19-vaccine-to-phase-2-trials-using-virus-like-particle-platform 2025-05-29T16:49:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dx-vx-advances-universal-covid-19-vaccine-to-phase-2-trials-using-virus-like-particle-platform 2025-05-29T16:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/cocrystal-pharma-s-cc-42344-shows-1000-fold-greater-potency-than-tamiflu-against-h5n1-avian-influenza 2025-05-29T16:49:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cocrystal-pharma-s-cc-42344-shows-1000-fold-greater-potency-than-tamiflu-against-h5n1-avian-influenza 2025-05-29T16:49:12+00:00 hourly 0.9 https://trial.medpath.com/news/bachem-expands-global-manufacturing-network-to-meet-surging-demand-for-peptide-and-oligonucleotide-therapeutics 2025-05-29T16:48:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bachem-expands-global-manufacturing-network-to-meet-surging-demand-for-peptide-and-oligonucleotide-therapeutics 2025-05-29T16:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-guides-extended-dosing-strategies-for-next-generation-anti-vegf-therapies-in-retinal-disease 2025-05-29T16:47:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-guides-extended-dosing-strategies-for-next-generation-anti-vegf-therapies-in-retinal-disease 2025-05-29T16:47:02+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-initiates-pivotal-phase-ii-iii-trial-of-brain-penetrant-tyk2-jak1-inhibitor-bhv-8000-for-early-parkinson-s-disease 2025-05-29T16:19:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-initiates-pivotal-phase-ii-iii-trial-of-brain-penetrant-tyk2-jak1-inhibitor-bhv-8000-for-early-parkinson-s-disease 2025-05-29T16:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/ochre-bio-strengthens-leadership-with-former-eli-lilly-and-astrazeneca-executive-as-rna-therapeutics-company-expands 2025-05-29T16:18:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ochre-bio-strengthens-leadership-with-former-eli-lilly-and-astrazeneca-executive-as-rna-therapeutics-company-expands 2025-05-29T16:18:50+00:00 hourly 0.9 https://trial.medpath.com/news/rona-therapeutics-reports-99-lipoprotein-a-reduction-with-annual-dose-rnai-therapy-rn026 2025-05-29T16:18:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rona-therapeutics-reports-99-lipoprotein-a-reduction-with-annual-dose-rnai-therapy-rn026 2025-05-29T16:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/inspira-technologies-accelerates-global-rollout-of-fda-cleared-art100-respiratory-support-system 2025-05-29T16:16:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inspira-technologies-accelerates-global-rollout-of-fda-cleared-art100-respiratory-support-system 2025-05-29T16:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/vima-therapeutics-emerges-with-60m-to-develop-first-oral-therapy-for-dystonia 2025-05-29T16:16:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vima-therapeutics-emerges-with-60m-to-develop-first-oral-therapy-for-dystonia 2025-05-29T16:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-7-year-post-market-study-for-brainsee-alzheimer-s-progression-prediction-tool 2025-05-29T16:16:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-7-year-post-market-study-for-brainsee-alzheimer-s-progression-prediction-tool 2025-05-29T16:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/beyfortus-demonstrates-superior-real-world-efficacy-against-rsv-compared-to-maternal-vaccination 2025-05-29T16:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyfortus-demonstrates-superior-real-world-efficacy-against-rsv-compared-to-maternal-vaccination 2025-05-29T16:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-s-lp-184-demonstrates-significant-survival-benefits-in-pediatric-brain-cancer-models 2025-05-29T16:15:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantern-pharma-s-lp-184-demonstrates-significant-survival-benefits-in-pediatric-brain-cancer-models 2025-05-29T16:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/uniqure-s-gene-therapy-amt-260-achieves-92-seizure-reduction-in-first-drug-resistant-epilepsy-patient 2025-05-29T16:15:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uniqure-s-gene-therapy-amt-260-achieves-92-seizure-reduction-in-first-drug-resistant-epilepsy-patient 2025-05-29T16:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/drug-farm-s-df-003-shows-promising-safety-profile-in-phase-1-trial-for-rare-rosah-syndrome 2025-05-29T15:58:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-farm-s-df-003-shows-promising-safety-profile-in-phase-1-trial-for-rare-rosah-syndrome 2025-05-29T15:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/estrella-immunopharma-advances-eb103-artemis-t-cell-therapy-to-second-cohort-in-starlight-1-trial-for-advanced-b-cell-lymphomas 2025-05-29T15:58:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/estrella-immunopharma-advances-eb103-artemis-t-cell-therapy-to-second-cohort-in-starlight-1-trial-for-advanced-b-cell-lymphomas 2025-05-29T15:58:03+00:00 hourly 0.9 https://trial.medpath.com/news/merck-and-daiichi-sankyo-withdraw-fda-application-for-lung-cancer-adc-after-survival-data-disappoints 2025-05-29T14:47:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-and-daiichi-sankyo-withdraw-fda-application-for-lung-cancer-adc-after-survival-data-disappoints 2025-05-29T14:47:08+00:00 hourly 0.9 https://trial.medpath.com/news/bioaffinity-technologies-secures-patent-for-dual-target-cancer-therapy-using-sirna-against-cd320-and-lrp2-receptors 2025-05-29T14:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioaffinity-technologies-secures-patent-for-dual-target-cancer-therapy-using-sirna-against-cd320-and-lrp2-receptors 2025-05-29T14:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionical-emas-secures-exclusive-partnership-to-address-critical-european-fluorouracil-shortage 2025-05-29T14:01:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionical-emas-secures-exclusive-partnership-to-address-critical-european-fluorouracil-shortage 2025-05-29T14:01:28+00:00 hourly 0.9 https://trial.medpath.com/news/iveena-submits-ind-application-for-novel-non-atropine-eye-drop-to-treat-pediatric-myopia 2025-05-29T14:00:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iveena-submits-ind-application-for-novel-non-atropine-eye-drop-to-treat-pediatric-myopia 2025-05-29T14:00:57+00:00 hourly 0.9 https://trial.medpath.com/news/iveena-announces-ind-submission-to-the-u-s-fda-for-a-phase-2 2025-05-29T14:00:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iveena-announces-ind-submission-to-the-u-s-fda-for-a-phase-2 2025-05-29T14:00:55+00:00 hourly 0.9 https://trial.medpath.com/news/kyzatrex-oral-testosterone-therapy-achieves-96-efficacy-rate-in-phase-3-trials-for-hypogonadism-treatment 2025-05-29T13:45:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyzatrex-oral-testosterone-therapy-achieves-96-efficacy-rate-in-phase-3-trials-for-hypogonadism-treatment 2025-05-29T13:45:16+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-faces-legal-challenges-as-study-links-depo-provera-to-increased-meningioma-risk 2025-05-29T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-faces-legal-challenges-as-study-links-depo-provera-to-increased-meningioma-risk 2025-05-29T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/sarvodaya-hospital-becomes-first-in-india-to-offer-terbium-161-psma-therapy-for-advanced-prostate-cancer 2025-05-29T12:39:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarvodaya-hospital-becomes-first-in-india-to-offer-terbium-161-psma-therapy-for-advanced-prostate-cancer 2025-05-29T12:39:53+00:00 hourly 0.9 https://trial.medpath.com/news/excyte-doses-first-patient-with-yk012-world-s-first-t-cell-engager-for-primary-membranous-nephropathy 2025-05-29T12:39:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/excyte-doses-first-patient-with-yk012-world-s-first-t-cell-engager-for-primary-membranous-nephropathy 2025-05-29T12:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-and-merck-withdraw-patritumab-deruxtecan-bla-after-phase-3-trial-fails-to-meet-overall-survival-endpoint 2025-05-29T12:38:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-and-merck-withdraw-patritumab-deruxtecan-bla-after-phase-3-trial-fails-to-meet-overall-survival-endpoint 2025-05-29T12:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/genor-biopharma-secures-nmpa-approval-for-lerociclib-cdk4-6-inhibitor-in-advanced-breast-cancer 2025-05-29T12:38:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genor-biopharma-secures-nmpa-approval-for-lerociclib-cdk4-6-inhibitor-in-advanced-breast-cancer 2025-05-29T12:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-mazdutide-achieves-breakthrough-as-world-s-first-gcg-glp-1-dual-receptor-agonist-for-weight-loss 2025-05-29T12:38:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-mazdutide-achieves-breakthrough-as-world-s-first-gcg-glp-1-dual-receptor-agonist-for-weight-loss 2025-05-29T12:38:07+00:00 hourly 0.9 https://trial.medpath.com/news/court-rulings-shape-patent-safe-harbor-provision-s-impact-on-pharmaceutical-development 2025-05-29T08:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/court-rulings-shape-patent-safe-harbor-provision-s-impact-on-pharmaceutical-development 2025-05-29T08:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/disc-medicine-presents-comprehensive-hematology-portfolio-data-at-eha-2025-congress 2025-05-29T05:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disc-medicine-presents-comprehensive-hematology-portfolio-data-at-eha-2025-congress 2025-05-29T05:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-clinical-trials-embrace-ai-and-digital-solutions-to-enhance-patient-centric-approaches 2025-05-29T04:46:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-clinical-trials-embrace-ai-and-digital-solutions-to-enhance-patient-centric-approaches 2025-05-29T04:46:04+00:00 hourly 0.9 https://trial.medpath.com/news/noxopharm-receives-ethics-approval-for-first-in-human-trial-of-sof-skn-in-cutaneous-lupus 2025-05-29T04:40:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/noxopharm-receives-ethics-approval-for-first-in-human-trial-of-sof-skn-in-cutaneous-lupus 2025-05-29T04:40:13+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-initiates-phase-3-trial-of-picankibart-for-psoriasis-patients-with-inadequate-il-17-response 2025-05-29T04:38:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-initiates-phase-3-trial-of-picankibart-for-psoriasis-patients-with-inadequate-il-17-response 2025-05-29T04:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/implantable-biobattery-achieves-99-6-tumor-reduction-in-breakthrough-drug-free-cancer-treatment 2025-05-29T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/implantable-biobattery-achieves-99-6-tumor-reduction-in-breakthrough-drug-free-cancer-treatment 2025-05-29T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/japan-launches-world-s-first-clinical-trials-for-artificial-blood-in-2025 2025-05-29T04:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-launches-world-s-first-clinical-trials-for-artificial-blood-in-2025 2025-05-29T04:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacists-lead-implementation-of-advanced-cell-and-gene-therapies-across-major-health-systems 2025-05-29T03:03:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacists-lead-implementation-of-advanced-cell-and-gene-therapies-across-major-health-systems 2025-05-29T03:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/iambic-therapeutics-showcases-ai-driven-drug-discovery-platform-at-multiple-investor-conferences 2025-05-29T02:42:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iambic-therapeutics-showcases-ai-driven-drug-discovery-platform-at-multiple-investor-conferences 2025-05-29T02:42:49+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-approaches-transform-bronchiectasis-management-as-research-centers-expand-nationwide 2025-05-29T02:42:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-approaches-transform-bronchiectasis-management-as-research-centers-expand-nationwide 2025-05-29T02:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/ultra-processed-foods-linked-to-increased-asthma-and-allergy-risk-in-children-research-shows 2025-05-29T02:42:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultra-processed-foods-linked-to-increased-asthma-and-allergy-risk-in-children-research-shows 2025-05-29T02:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/oral-ritlecitinib-combined-with-phototherapy-shows-enhanced-repigmentation-in-nonsegmental-vitiligo 2025-05-29T02:42:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-ritlecitinib-combined-with-phototherapy-shows-enhanced-repigmentation-in-nonsegmental-vitiligo 2025-05-29T02:42:38+00:00 hourly 0.9 https://trial.medpath.com/news/epivax-appoints-dr-vibha-jawa-as-chief-scientific-officer-to-lead-immunogenicity-strategy 2025-05-29T02:42:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epivax-appoints-dr-vibha-jawa-as-chief-scientific-officer-to-lead-immunogenicity-strategy 2025-05-29T02:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/first-line-treatment-options-for-metastatic-pancreatic 2025-05-29T02:04:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-line-treatment-options-for-metastatic-pancreatic 2025-05-29T02:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-links-covid-19-infection-and-adenoviral-vaccines-to-guillain-barre-syndrome-risk-clears-mrna-vaccines 2025-05-29T00:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-study-links-covid-19-infection-and-adenoviral-vaccines-to-guillain-barre-syndrome-risk-clears-mrna-vaccines 2025-05-29T00:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-cancels-590-million-moderna-bird-flu-vaccine-contract-amid-mrna-technology-review 2025-05-29T00:47:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-cancels-590-million-moderna-bird-flu-vaccine-contract-amid-mrna-technology-review 2025-05-29T00:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/supernus-faces-generic-competition-as-third-parties-file-anda-challenges-for-adhd-drug-qelbree 2025-05-29T00:47:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supernus-faces-generic-competition-as-third-parties-file-anda-challenges-for-adhd-drug-qelbree 2025-05-29T00:47:44+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-and-merck-secure-patent-victory-blocking-lenvima-generic-until-2036 2025-05-29T00:47:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-and-merck-secure-patent-victory-blocking-lenvima-generic-until-2036 2025-05-29T00:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-menopause-drug-duavee-shows-promise-for-breast-cancer-prevention-in-phase-2-trial 2025-05-29T00:47:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-menopause-drug-duavee-shows-promise-for-breast-cancer-prevention-in-phase-2-trial 2025-05-29T00:47:23+00:00 hourly 0.9 https://trial.medpath.com/news/ausperbio-secures-50-million-series-b-funding-to-advance-hepatitis-b-functional-cure-candidate-ahb-137 2025-05-29T00:46:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ausperbio-secures-50-million-series-b-funding-to-advance-hepatitis-b-functional-cure-candidate-ahb-137 2025-05-29T00:46:44+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-raises-695000-in-private-placement-to-fund-phase-ii-thio-101-cancer-trial 2025-05-29T00:46:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-raises-695000-in-private-placement-to-fund-phase-ii-thio-101-cancer-trial 2025-05-29T00:46:33+00:00 hourly 0.9 https://trial.medpath.com/news/coremap-receives-fda-ide-approval-to-expand-novel-atrial-fibrillation-mapping-technology-study-to-u-s 2025-05-29T00:46:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coremap-receives-fda-ide-approval-to-expand-novel-atrial-fibrillation-mapping-technology-study-to-u-s 2025-05-29T00:46:15+00:00 hourly 0.9 https://trial.medpath.com/news/eton-pharmaceuticals-receives-fda-approval-for-khindivi-first-hydrocortisone-oral-solution-for-pediatric-adrenal-insufficiency 2025-05-29T00:45:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eton-pharmaceuticals-receives-fda-approval-for-khindivi-first-hydrocortisone-oral-solution-for-pediatric-adrenal-insufficiency 2025-05-29T00:45:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-in-class-trpm8-receptor-agonist-tryptyr-for-dry-eye-disease-treatment 2025-05-29T00:45:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-in-class-trpm8-receptor-agonist-tryptyr-for-dry-eye-disease-treatment 2025-05-29T00:45:51+00:00 hourly 0.9 https://trial.medpath.com/news/armored-anti-gpc3-jw-004-shows-increased-potency-against-hcc-bioworld 2025-05-29T00:45:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/armored-anti-gpc3-jw-004-shows-increased-potency-against-hcc-bioworld 2025-05-29T00:45:35+00:00 hourly 0.9 https://trial.medpath.com/news/ira-biosimilar-incentives-drive-measurable-uptake-in-us-healthcare-facilities 2025-05-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ira-biosimilar-incentives-drive-measurable-uptake-in-us-healthcare-facilities 2025-05-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-and-chdi-foundation-extend-multi-decade 2025-05-28T22:45:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charles-river-and-chdi-foundation-extend-multi-decade 2025-05-28T22:45:21+00:00 hourly 0.9 https://trial.medpath.com/news/cessatech-raises-dkk-14-8-million-to-accelerate-u-s-commercial-launch-of-pediatric-pain-treatment-ct001 2025-05-28T22:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cessatech-raises-dkk-14-8-million-to-accelerate-u-s-commercial-launch-of-pediatric-pain-treatment-ct001 2025-05-28T22:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/javara-secures-series-c-funding-to-expand-community-based-clinical-trial-access-into-oncology-and-cns 2025-05-28T21:46:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/javara-secures-series-c-funding-to-expand-community-based-clinical-trial-access-into-oncology-and-cns 2025-05-28T21:46:31+00:00 hourly 0.9 https://trial.medpath.com/news/wacker-biotech-and-expression-manufacturing-form-strategic-partnership-to-accelerate-lentiviral-gene-therapy-development 2025-05-28T21:45:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wacker-biotech-and-expression-manufacturing-form-strategic-partnership-to-accelerate-lentiviral-gene-therapy-development 2025-05-28T21:45:47+00:00 hourly 0.9 https://trial.medpath.com/news/canada-launches-first-home-based-cancer-immunotherapy-trial-using-subcutaneous-injection 2025-05-28T20:49:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-launches-first-home-based-cancer-immunotherapy-trial-using-subcutaneous-injection 2025-05-28T20:49:50+00:00 hourly 0.9 https://trial.medpath.com/news/therapeutic-plasma-exchange-combined-with-immunoglobulin-reduces-biological-age-by-2-6-years-in-clinical-trial 2025-05-28T20:49:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therapeutic-plasma-exchange-combined-with-immunoglobulin-reduces-biological-age-by-2-6-years-in-clinical-trial 2025-05-28T20:49:31+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-achieve-first-ever-production-of-human-dnase1-in-yeast-offering-cost-effective-alternative-to-hamster-cell-manufacturing 2025-05-28T20:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-achieve-first-ever-production-of-human-dnase1-in-yeast-offering-cost-effective-alternative-to-hamster-cell-manufacturing 2025-05-28T20:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/texas-approves-50-million-for-ibogaine-research-initiative-largest-state-funded-psychedelic-program-in-us-history 2025-05-28T20:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-approves-50-million-for-ibogaine-research-initiative-largest-state-funded-psychedelic-program-in-us-history 2025-05-28T20:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/wave-life-sciences-announces-appointment-of-dr-christopher-wright-as-chief-medical-officer 2025-05-28T20:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wave-life-sciences-announces-appointment-of-dr-christopher-wright-as-chief-medical-officer 2025-05-28T20:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/stereotactic-radiation-therapy-shows-superior-quality-of-life-benefits-over-hippocampal-avoidance-wbrt-in-brain-metastases-trial 2025-05-28T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stereotactic-radiation-therapy-shows-superior-quality-of-life-benefits-over-hippocampal-avoidance-wbrt-in-brain-metastases-trial 2025-05-28T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hyperfine-receives-fda-clearance-for-ai-enhanced-portable-mri-software-approaching-conventional-scanner-quality 2025-05-28T19:44:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hyperfine-receives-fda-clearance-for-ai-enhanced-portable-mri-software-approaching-conventional-scanner-quality 2025-05-28T19:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/enthera-pharmaceuticals-announces-publication-in-the-journal-of-clinical-investigation-supporting-the-clinical-development-of-ebrasodebart 2025-05-28T18:47:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enthera-pharmaceuticals-announces-publication-in-the-journal-of-clinical-investigation-supporting-the-clinical-development-of-ebrasodebart 2025-05-28T18:47:01+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-discover-critical-window-for-in-vivo-gene-therapy-in-newborns 2025-05-28T18:46:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-discover-critical-window-for-in-vivo-gene-therapy-in-newborns 2025-05-28T18:46:58+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-acquires-30-million-mezagitamab-rights-from-bioinvent-as-anti-cd38-antibody-advances-to-phase-3 2025-05-28T18:46:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-royalty-acquires-30-million-mezagitamab-rights-from-bioinvent-as-anti-cd38-antibody-advances-to-phase-3 2025-05-28T18:46:27+00:00 hourly 0.9 https://trial.medpath.com/news/egypt-s-holdipharma-forms-strategic-joint-venture-with-us-partner-to-enter-north-american-and-european-markets 2025-05-28T18:45:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egypt-s-holdipharma-forms-strategic-joint-venture-with-us-partner-to-enter-north-american-and-european-markets 2025-05-28T18:45:40+00:00 hourly 0.9 https://trial.medpath.com/news/bora-pharmaceuticals-expands-sterile-fill-finish-capacity-in-baltimore-to-meet-growing-demand-for-high-value-drug-products 2025-05-28T17:55:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bora-pharmaceuticals-expands-sterile-fill-finish-capacity-in-baltimore-to-meet-growing-demand-for-high-value-drug-products 2025-05-28T17:55:30+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-discontinues-acurate-tavr-program-after-clinical-trial-failure 2025-05-28T17:53:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-discontinues-acurate-tavr-program-after-clinical-trial-failure 2025-05-28T17:53:56+00:00 hourly 0.9 https://trial.medpath.com/news/proteinqure-secures-11m-series-a-to-advance-first-ai-designed-peptide-therapeutic-for-triple-negative-breast-cancer 2025-05-28T17:53:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteinqure-secures-11m-series-a-to-advance-first-ai-designed-peptide-therapeutic-for-triple-negative-breast-cancer 2025-05-28T17:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-drug-combination-extends-mouse-lifespan-by-30-in-aging-research-breakthrough 2025-05-28T17:05:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-drug-combination-extends-mouse-lifespan-by-30-in-aging-research-breakthrough 2025-05-28T17:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/aphios-receives-u-s-patent-allowance-for-room-temperature-stable-single-shot-mrna-covid-19-vaccine 2025-05-28T16:51:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aphios-receives-u-s-patent-allowance-for-room-temperature-stable-single-shot-mrna-covid-19-vaccine 2025-05-28T16:51:29+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-clinical-decision-support-system-accelerates-bacteremia-treatment-by-29-hours-in-groundbreaking-study 2025-05-28T16:51:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-clinical-decision-support-system-accelerates-bacteremia-treatment-by-29-hours-in-groundbreaking-study 2025-05-28T16:51:17+00:00 hourly 0.9 https://trial.medpath.com/news/carb-x-awards-debiopharm-additional-12-3-million-to-advance-novel-antibiotic-debio-1453-against-drug-resistant-gonorrhea 2025-05-28T16:51:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carb-x-awards-debiopharm-additional-12-3-million-to-advance-novel-antibiotic-debio-1453-against-drug-resistant-gonorrhea 2025-05-28T16:51:16+00:00 hourly 0.9 https://trial.medpath.com/news/monarch-therapeutics-and-snap-biosciences-partner-to-advance-car-nk-cell-therapy-with-small-molecule-adaptor-technology 2025-05-28T16:50:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monarch-therapeutics-and-snap-biosciences-partner-to-advance-car-nk-cell-therapy-with-small-molecule-adaptor-technology 2025-05-28T16:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/hillstar-bio-strengthens-leadership-team-with-key-appointments-to-advance-precision-immunotherapy-pipeline 2025-05-28T16:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hillstar-bio-strengthens-leadership-team-with-key-appointments-to-advance-precision-immunotherapy-pipeline 2025-05-28T16:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-aligns-with-olema-on-90mg-palazestrant-dose-for-phase-3-breast-cancer-trials 2025-05-28T16:49:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-aligns-with-olema-on-90mg-palazestrant-dose-for-phase-3-breast-cancer-trials 2025-05-28T16:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/octapharma-s-panzyga-shows-mixed-results-in-phase-3-pans-trial-achieves-significant-secondary-endpoint 2025-05-28T16:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/octapharma-s-panzyga-shows-mixed-results-in-phase-3-pans-trial-achieves-significant-secondary-endpoint 2025-05-28T16:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/archeus-technologies-and-warf-partner-to-advance-novel-prostate-cancer-radiopharmaceutical-art-101-into-phase-1-trials 2025-05-28T16:49:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/archeus-technologies-and-warf-partner-to-advance-novel-prostate-cancer-radiopharmaceutical-art-101-into-phase-1-trials 2025-05-28T16:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/veru-s-enobosarm-shows-improved-safety-profile-in-combination-with-wegovy-for-muscle-preserving-obesity-treatment 2025-05-28T16:49:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veru-s-enobosarm-shows-improved-safety-profile-in-combination-with-wegovy-for-muscle-preserving-obesity-treatment 2025-05-28T16:49:21+00:00 hourly 0.9 https://trial.medpath.com/news/tpn-101-selected-for-healey-als-platform-trial-following-promising-phase-2-results-in-c9orf72-related-als 2025-05-28T16:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tpn-101-selected-for-healey-als-platform-trial-following-promising-phase-2-results-in-c9orf72-related-als 2025-05-28T16:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-phase-1b-trial-for-novel-nectin-4-targeted-radiopharmaceutical-aky-1189-across-multiple-cancer-types 2025-05-28T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-phase-1b-trial-for-novel-nectin-4-targeted-radiopharmaceutical-aky-1189-across-multiple-cancer-types 2025-05-28T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/lumanity-and-parker-institute-form-strategic-alliance-to-accelerate-cancer-immunotherapy-development 2025-05-28T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumanity-and-parker-institute-form-strategic-alliance-to-accelerate-cancer-immunotherapy-development 2025-05-28T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-advances-sirt6-gene-therapy-pipeline-with-strategic-partnerships-and-patent-expansion 2025-05-28T16:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genflow-biosciences-advances-sirt6-gene-therapy-pipeline-with-strategic-partnerships-and-patent-expansion 2025-05-28T16:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/incannex-eliminates-347-million-share-dilution-ahead-of-pivotal-sleep-apnea-drug-trial-results 2025-05-28T16:47:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incannex-eliminates-347-million-share-dilution-ahead-of-pivotal-sleep-apnea-drug-trial-results 2025-05-28T16:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-eb-003-shows-statistically-significant-antidepressant-effects-in-preclinical-depression-model 2025-05-28T16:46:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveric-biosciences-eb-003-shows-statistically-significant-antidepressant-effects-in-preclinical-depression-model 2025-05-28T16:46:56+00:00 hourly 0.9 https://trial.medpath.com/news/collplant-advances-regenerative-breast-implant-technology-with-promising-preclinical-results 2025-05-28T16:46:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/collplant-advances-regenerative-breast-implant-technology-with-promising-preclinical-results 2025-05-28T16:46:25+00:00 hourly 0.9 https://trial.medpath.com/news/tq-therapeutics-acquires-juno-gmbh-to-advance-decentralized-cell-therapy-platform 2025-05-28T16:46:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tq-therapeutics-acquires-juno-gmbh-to-advance-decentralized-cell-therapy-platform 2025-05-28T16:46:23+00:00 hourly 0.9 https://trial.medpath.com/news/enveda-s-ai-discovered-anti-inflammatory-env-294-clears-phase-1-safety-trial-advances-to-atopic-dermatitis-study 2025-05-28T16:46:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveda-s-ai-discovered-anti-inflammatory-env-294-clears-phase-1-safety-trial-advances-to-atopic-dermatitis-study 2025-05-28T16:46:19+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-novel-adcs-show-promising-early-clinical-results-with-topoix-payload-technology 2025-05-28T16:21:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-s-novel-adcs-show-promising-early-clinical-results-with-topoix-payload-technology 2025-05-28T16:21:11+00:00 hourly 0.9 https://trial.medpath.com/news/debra-research-and-dermaliq-partner-to-develop-touchless-drug-delivery-for-epidermolysis-bullosa 2025-05-28T16:21:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/debra-research-and-dermaliq-partner-to-develop-touchless-drug-delivery-for-epidermolysis-bullosa 2025-05-28T16:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/biostem-technologies-receives-patent-allowances-for-novel-fenestrated-placental-allografts 2025-05-28T16:20:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostem-technologies-receives-patent-allowances-for-novel-fenestrated-placental-allografts 2025-05-28T16:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-partners-with-telesis-bio-to-deploy-revolutionary-dna-synthesis-platform-for-accelerated-drug-development 2025-05-28T16:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-partners-with-telesis-bio-to-deploy-revolutionary-dna-synthesis-platform-for-accelerated-drug-development 2025-05-28T16:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/radyus-research-and-eurofins-cdmo-alphora-form-strategic-partnership-to-accelerate-early-stage-drug-development 2025-05-28T16:19:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radyus-research-and-eurofins-cdmo-alphora-form-strategic-partnership-to-accelerate-early-stage-drug-development 2025-05-28T16:19:58+00:00 hourly 0.9 https://trial.medpath.com/news/nuclera-and-cytiva-partnership-reduces-protein-characterization-timeline-from-months-to-five-days 2025-05-28T16:19:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclera-and-cytiva-partnership-reduces-protein-characterization-timeline-from-months-to-five-days 2025-05-28T16:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/redeye-synact-pharma-q1-2025-new-phase-ii-study-in-dengue-fever-tradingview 2025-05-28T16:18:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redeye-synact-pharma-q1-2025-new-phase-ii-study-in-dengue-fever-tradingview 2025-05-28T16:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/distalmotion-receives-fda-510-k-clearance-for-dexter-robotic-surgery-system-in-cholecystectomy 2025-05-28T16:17:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/distalmotion-receives-fda-510-k-clearance-for-dexter-robotic-surgery-system-in-cholecystectomy 2025-05-28T16:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-and-advanz-pharma-expand-13-8-billion-biosimilar-partnership-with-three-new-candidates 2025-05-28T16:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-and-advanz-pharma-expand-13-8-billion-biosimilar-partnership-with-three-new-candidates 2025-05-28T16:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/aspire-biopharma-holdings-inc-provides-development-update-on-buzz-bomb-tm-usa-today 2025-05-28T16:17:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspire-biopharma-holdings-inc-provides-development-update-on-buzz-bomb-tm-usa-today 2025-05-28T16:17:15+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-infiltrating-lymphocytes-emerge-as-key-biomarkers-for-nsclc-immunotherapy-response 2025-05-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-infiltrating-lymphocytes-emerge-as-key-biomarkers-for-nsclc-immunotherapy-response 2025-05-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/australian-developed-pill-could-ease-distressing-behaviours-in 2025-05-28T15:38:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-developed-pill-could-ease-distressing-behaviours-in 2025-05-28T15:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-tebipenem-hbr-phase-iii-trial-stopped-early-for-efficacy-in-complicated-uti-treatment 2025-05-28T15:15:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-tebipenem-hbr-phase-iii-trial-stopped-early-for-efficacy-in-complicated-uti-treatment 2025-05-28T15:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/german-radiopharmaceutical-biotech-itm-secures-262-5m-debt-financing-to-advance-cancer-treatment-technologies 2025-05-28T14:44:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/german-radiopharmaceutical-biotech-itm-secures-262-5m-debt-financing-to-advance-cancer-treatment-technologies 2025-05-28T14:44:42+00:00 hourly 0.9 https://trial.medpath.com/news/medable-launches-digital-platform-to-address-20-dropout-rate-in-cell-and-gene-therapy-long-term-follow-up-studies 2025-05-28T14:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medable-launches-digital-platform-to-address-20-dropout-rate-in-cell-and-gene-therapy-long-term-follow-up-studies 2025-05-28T14:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-evaluates-host-directed-therapies-for-rifampicin-resistant-tuberculosis 2025-05-28T12:41:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-evaluates-host-directed-therapies-for-rifampicin-resistant-tuberculosis 2025-05-28T12:41:08+00:00 hourly 0.9 https://trial.medpath.com/news/pimicotinib-achieves-54-response-rate-in-phase-3-trial-for-rare-joint-tumor 2025-05-28T12:40:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pimicotinib-achieves-54-response-rate-in-phase-3-trial-for-rare-joint-tumor 2025-05-28T12:40:51+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-reports-promising-phase-1-data-for-novel-mrna-cancer-therapy-stx-001 2025-05-28T12:40:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strand-therapeutics-reports-promising-phase-1-data-for-novel-mrna-cancer-therapy-stx-001 2025-05-28T12:40:45+00:00 hourly 0.9 https://trial.medpath.com/news/st-george-s-hospital-achieves-majority-remission-rate-in-first-car-t-cell-therapy-patients 2025-05-28T12:40:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-george-s-hospital-achieves-majority-remission-rate-in-first-car-t-cell-therapy-patients 2025-05-28T12:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/alamar-biosciences-partners-with-scilifelab-to-advance-precision-proteomics-for-early-disease-detection 2025-05-28T12:40:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alamar-biosciences-partners-with-scilifelab-to-advance-precision-proteomics-for-early-disease-detection 2025-05-28T12:40:03+00:00 hourly 0.9 https://trial.medpath.com/news/ttf-1-biomarker-predicts-survival-outcomes-for-kras-inhibitor-sotorasib-in-lung-cancer 2025-05-28T12:40:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ttf-1-biomarker-predicts-survival-outcomes-for-kras-inhibitor-sotorasib-in-lung-cancer 2025-05-28T12:40:02+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-launches-7-tender-offer-for-regulus-therapeutics-with-additional-regulatory-milestone-payment 2025-05-28T12:39:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-launches-7-tender-offer-for-regulus-therapeutics-with-additional-regulatory-milestone-payment 2025-05-28T12:39:19+00:00 hourly 0.9 https://trial.medpath.com/news/arcticzymes-and-austrian-centre-extend-partnership-to-advance-bionanoparticle-purification-for-gene-therapies 2025-05-28T12:38:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcticzymes-and-austrian-centre-extend-partnership-to-advance-bionanoparticle-purification-for-gene-therapies 2025-05-28T12:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/british-columbia-biosimilar-policy-shows-no-impact-on-healthcare-utilization-for-inflammatory-arthritis-patients 2025-05-28T12:37:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/british-columbia-biosimilar-policy-shows-no-impact-on-healthcare-utilization-for-inflammatory-arthritis-patients 2025-05-28T12:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-to-present-clinical-data-on-rare-disease-therapies-at-eular-2025 2025-05-28T12:37:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sobi-to-present-clinical-data-on-rare-disease-therapies-at-eular-2025 2025-05-28T12:37:52+00:00 hourly 0.9 https://trial.medpath.com/news/efficacy-and-safety-of-a-house-dust-mites-allergoid-in-patients-with-allergic-rhinitis 2025-05-28T12:37:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efficacy-and-safety-of-a-house-dust-mites-allergoid-in-patients-with-allergic-rhinitis 2025-05-28T12:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/bd-launches-xtract-registry-to-evaluate-real-world-outcomes-of-rotarex-atherectomy-system-in-peripheral-artery-disease 2025-05-28T12:37:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-launches-xtract-registry-to-evaluate-real-world-outcomes-of-rotarex-atherectomy-system-in-peripheral-artery-disease 2025-05-28T12:37:49+00:00 hourly 0.9 https://trial.medpath.com/news/french-biotech-kyron-bio-raises-eur5-5m-to-advance-glycan-controlled-antibody-therapeutics 2025-05-28T08:44:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/french-biotech-kyron-bio-raises-eur5-5m-to-advance-glycan-controlled-antibody-therapeutics 2025-05-28T08:44:32+00:00 hourly 0.9 https://trial.medpath.com/news/blinatumomab-combination-therapy-wins-prestigious-trial-of-the-year-award-for-pediatric-leukemia-breakthrough 2025-05-28T08:43:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blinatumomab-combination-therapy-wins-prestigious-trial-of-the-year-award-for-pediatric-leukemia-breakthrough 2025-05-28T08:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-s-ebc-129-antibody-drug-conjugate-receives-fda-fast-track-designation-for-pancreatic-cancer-treatment 2025-05-28T08:15:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-s-ebc-129-antibody-drug-conjugate-receives-fda-fast-track-designation-for-pancreatic-cancer-treatment 2025-05-28T08:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/portal-access-secures-7m-series-a-to-advance-next-generation-chemotherapy-port-through-fda-approval 2025-05-28T08:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/portal-access-secures-7m-series-a-to-advance-next-generation-chemotherapy-port-through-fda-approval 2025-05-28T08:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-partners-with-city-therapeutics-to-develop-rnai-therapies-for-central-nervous-system-diseases 2025-05-28T04:58:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-partners-with-city-therapeutics-to-develop-rnai-therapies-for-central-nervous-system-diseases 2025-05-28T04:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/japan-s-intellectual-property-high-court-orders-y-21-7-billion-patent-infringement-payout-for-toray-s-anti-itch-drug 2025-05-28T04:43:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-s-intellectual-property-high-court-orders-y-21-7-billion-patent-infringement-payout-for-toray-s-anti-itch-drug 2025-05-28T04:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/olympus-receives-fda-clearance-for-advanced-edof-endoscopy-technology-to-enhance-gi-lesion-detection 2025-05-28T04:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olympus-receives-fda-clearance-for-advanced-edof-endoscopy-technology-to-enhance-gi-lesion-detection 2025-05-28T04:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-ai-platform-cuts-clinical-audit-time-by-90-partners-with-roche-for-clinical-trial-acceleration 2025-05-28T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-ai-platform-cuts-clinical-audit-time-by-90-partners-with-roche-for-clinical-trial-acceleration 2025-05-28T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/oncologists-address-diagnostic-challenges-and-treatment-advances-in-nasopharyngeal-cancer 2025-05-28T03:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncologists-address-diagnostic-challenges-and-treatment-advances-in-nasopharyngeal-cancer 2025-05-28T03:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-advances-lyme-disease-vaccine-vla15-with-pfizer-partnership-as-phase-3-data-expected-by-end-of-2025 2025-05-28T03:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-advances-lyme-disease-vaccine-vla15-with-pfizer-partnership-as-phase-3-data-expected-by-end-of-2025 2025-05-28T03:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/community-oncology-practices-expand-access-to-car-t-and-bispecific-therapies-as-workforce-challenges-persist 2025-05-28T02:37:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-oncology-practices-expand-access-to-car-t-and-bispecific-therapies-as-workforce-challenges-persist 2025-05-28T02:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-appoints-bristol-myers-squibb-veteran-to-lead-rare-disease-commercial-strategy 2025-05-28T02:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-appoints-bristol-myers-squibb-veteran-to-lead-rare-disease-commercial-strategy 2025-05-28T02:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/salvia-raises-60m-for-neuromodulation-migraine-system 2025-05-28T01:48:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salvia-raises-60m-for-neuromodulation-migraine-system 2025-05-28T01:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-sequoia-data-confirms-zanubrutinib-s-long-term-efficacy-in-high-risk-cll-sll-patients 2025-05-28T00:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-year-sequoia-data-confirms-zanubrutinib-s-long-term-efficacy-in-high-risk-cll-sll-patients 2025-05-28T00:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-advances-imetelstat-as-potential-game-changer-for-jak-inhibitor-resistant-myelofibrosis 2025-05-28T00:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-advances-imetelstat-as-potential-game-changer-for-jak-inhibitor-resistant-myelofibrosis 2025-05-28T00:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-teva-s-tev-53408-for-celiac-disease-treatment 2025-05-28T00:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-teva-s-tev-53408-for-celiac-disease-treatment 2025-05-28T00:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-solutions-transform-pharmaceutical-supply-chain-management-amid-growing-disruptions 2025-05-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-solutions-transform-pharmaceutical-supply-chain-management-amid-growing-disruptions 2025-05-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-develop-in-vivo-car-t-cell-engineering-to-reduce-cancer-treatment-costs-and-complexity 2025-05-27T23:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-develop-in-vivo-car-t-cell-engineering-to-reduce-cancer-treatment-costs-and-complexity 2025-05-27T23:04:17+00:00 hourly 0.9